Cipla Enters India’s Weight-Loss Segment with ‘Yurpeak’, a Repurposed Version of Mounjaro
India’s weight-loss market has welcomed a new player with the launch of ‘Yurpeak’ by Cipla, a popular pharmaceutical company. Yurpeak is the brand name given to the medication Mounjaro, which has been approved by the US FDA for the treatment of type 2 diabetes. However, its effectiveness in weight loss has also been widely recognized. With the introduction of Yurpeak, Cipla aims to tap into the growing demand for weight-loss solutions in India.
Mounjaro, the original medication, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels and promotes weight loss. Clinical trials have shown that Mounjaro can lead to significant weight loss, with some patients losing up to 15-20% of their body weight. This has generated significant interest in the medication as a potential treatment option for obesity.
Cipla’s entry into the weight-loss market with Yurpeak is strategic, given the increasing prevalence of obesity and related health issues in India. The country is home to a large population struggling with weight-related problems, and the market for weight-loss solutions is expected to grow significantly in the coming years. By launching Yurpeak, Cipla is poised to capitalize on this trend and establish itself as a major player in the Indian weight-loss market.
The launch of Yurpeak is also expected to increase awareness about the importance of weight management and the availability of effective treatment options. Cipla plans to promote Yurpeak through a targeted marketing campaign, highlighting its benefits and effectiveness in weight loss. The company will also engage with healthcare professionals to educate them about the medication and its potential to address the growing obesity epidemic in India.
While the launch of Yurpeak is a significant development in India’s weight-loss market, it is essential to note that the medication should only be used under medical supervision. As with any prescription medication, there may be potential side effects and risks associated with Yurpeak, and patients should consult their healthcare provider before starting treatment.
In conclusion, the launch of Yurpeak by Cipla marks a new era in India’s weight-loss market. With its proven effectiveness in weight loss and Cipla’s strong presence in the Indian pharmaceutical market, Yurpeak is expected to make a significant impact on the country’s obesity landscape. As the demand for weight-loss solutions continues to grow, Cipla is well-positioned to capitalize on this trend and establish itself as a leader in the Indian weight-loss market.
DK Shivakumar, DCM, holds meeting with industry leaders to address Bengaluru’s infrastructure concerns
In a bid to address the concerns of industrialists over Bengaluru’s poor infrastructure, Deputy Chief Minister DK Shivakumar held a meeting with prominent business leaders, including Biocon founder Kiran Mazumdar-Shaw and former Infosys CFO Mohandas Pai. The meeting, which took place over dinner on Saturday, aimed to discuss the city’s key infrastructure bottlenecks, including potholes, traffic, and garbage management. The gathering was also attended by Greater Bengaluru Authority Chief Commissioner M Maheshwar Rao, Bengaluru Business Corridor Chairman LK Atheeq, and former JDS spokesperson Tanveer Ahmed, among others.
The meeting was a response to recent criticism from Kiran and Pai, who had expressed their frustration over the city’s infrastructure issues. Their comments had sparked a backlash from Congress ministers, who suggested that they should use their corporate social responsibility (CSR) funds to contribute to the city’s development. However, the tone of the meeting was constructive, with Kiran Mazumdar-Shaw describing it as a positive discussion on an action plan to address the city’s key infrastructure challenges.
Shivakumar acknowledged that the criticism from industrialists had gained international attention, and emphasized the need to work together to find solutions. He appreciated the suggestions offered by the business leaders and announced that they would be included in the main advisory committee to contribute to the city’s development. The Deputy Chief Minister recognized that the challenge lies in working through the bureaucratic framework, which can be time-consuming due to the need to follow legal protocols.
The meeting marks a significant step towards collaboration between the government and the business community in addressing Bengaluru’s infrastructure woes. By engaging with prominent industrialists and incorporating their suggestions, the government aims to find effective solutions to the city’s problems and improve its overall development. The inclusion of business leaders in the advisory committee is expected to bring in fresh perspectives and expertise, ultimately contributing to the betterment of Bengaluru’s infrastructure.
Biography, Family Background, Professional Journey, Wealth, and Other Interesting Facts
Upasana Kamineni Konidela is a renowned businesswoman, philanthropist, and spouse of South Indian superstar Ram Charan Teja. Born on July 20, 1989, in Hyderabad, she hails from one of India’s most influential families. Her great-grandfather, Dr. Prathap C. Reddy, founded Apollo Hospitals, a leading hospital chain in India. Upasana’s parents, Anil Kamineni and Shobana Kamineni, are also prominent figures in their respective business sectors.
Upasana graduated from Regent’s University in London with a degree in business and marketing. She began her career in the hospital industry and is currently the Vice Chairperson of Apollo Life. She is also the Editor-in-Chief of B Positive Magazine, advocating for holistic health, sustainability, and mental wellness. Through the Apollo Foundation, she provides medical aid and awareness to marginalized communities, contributing significantly to corporate wellness and employee productivity in India.
Upasana’s philanthropic efforts have earned her the Dadasaheb Phalke Award for Benefactor of the Year. She married Ram Charan Teja in 2012, and the couple has a daughter, Klin Kaara Konidela, born in June 2023. Upasana’s estimated net worth is between $100 million, derived from her stake in Apollo Hospitals, business leadership roles, and investments.
Apart from her professional achievements, Upasana is known for her innate beauty and sophisticated fashion sense. She stands at 173 cm, weighs around 55 kg, and has dark brown hair and brown eyes. As a mother, she has been showered with congratulations from fans and well-wishers on social media, marking a new era for the Konidela family. Upasana’s family includes her father, Anil Kamineni; mother, Shobana Kamineni; brother, Puansh Kamineni; and husband, Ram Charan Teja. Her sisters-in-law are Sushmita Konidela and Sreeja Kalyan.
Upasana’s commitment to wellness, sustainability, and social entrepreneurship has made her a respected figure in India. Her leadership roles in Apollo Life and the Apollo Foundation demonstrate her dedication to improving healthcare and community welfare. As a member of one of India’s most influential families, Upasana has carved out her own path, making a significant impact in the fields of healthcare, wellness, and social entrepreneurship.
Glenmark Pharmaceuticals Inc., USA will introduce Ropivacaine Hydrochloride Injection USP in three concentrations: 2mg/mL, 5mg/mL, and 10mg/mL, available in 20mL and 30mL single-dose vials.
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Ropivacaine Hydrochloride Injection USP, a generic version of Naropin Injection, in November 2025. The new product will be available in three strengths: 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. According to IQVIA sales data, the Naropin Injection market achieved annual sales of approximately $20.9 million for the 12-month period ending August 2025.
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to Naropin Injection, making it a quality and affordable alternative for patients. The launch of this product represents another important addition to Glenmark’s expanding injectable portfolio, reinforcing the company’s dedication to providing quality and affordable alternatives to market for patients in need.
Marc Kikuchi, President & Business Head, North America, commented on the launch, stating that the company is pleased to announce the launch of Ropivacaine Hydrochloride Injection USP. Glenmark’s product is only approved for the indications listed in the company’s approved label, which may not include all the indications for the reference listed drug, Naropin Injection.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments, focusing on therapeutic areas such as respiratory, dermatology, and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark has been recognized as one of the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023 and one of the Top 50 Generics and biosimilar companies ranked by sales in 2024.
The company has also made a commitment to reduce its Green House Gas (GHG) emission, with targets approved by the Science Based Target initiative (SBTi) in 2023. Glenmark’s CSR interventions have impacted over 3.3 million lives over the last decade. The company can be found on LinkedIn and Instagram, and more information is available on their website, www.glenmarkpharma.com.
Apollo Hospitals organizes a cardiac rehabilitation run at Necklace Road to raise awareness about heart health.
On September 21, 2025, Apollo Hospitals in Hyderabad organized a ‘Cardiac Rehab Run’ at Necklace Road, aiming to promote awareness about preventing heart attacks and supporting free rehab for underprivileged patients. The event brought together cardiac patients, fitness enthusiasts, doctors, and people from all walks of life to showcase that individuals can lead active lives even after experiencing a heart episode.
The run was held in association with the Cardiac Rehab Foundation and featured talks, survivor stories, and fitness demonstrations. According to doctors, 90% of heart attacks can be prevented with awareness and structured rehab programs. However, despite being a WHO Class 1A recommended initiative, cardiac rehab remains underutilized in India.
Dr. Rajeev Garg, a senior cardiologist at Apollo Hospitals, emphasized that rehabilitation is not only for post-surgery patients but also for those who want to prevent a cardiac episode. The hospital’s Regional CEO, Tejesvi Rao Veerapalli, highlighted that the event included awareness talks and stories from heart survivors, promoting the importance of cardiac rehab.
The Regional COO, Dr. Rachapalli Reddyappa Reddy, shared inspiring stories of heart patients who underwent rehab and transformed their lives. Some of these patients have even started participating in marathons, demonstrating the effectiveness of cardiac rehab programs. The ‘Cardiac Rehab Run’ served as a platform to raise funds for free rehab services for underprivileged patients, promoting a healthier and more active lifestyle for individuals with heart conditions.
By organizing this event, Apollo Hospitals aimed to spread awareness about the importance of preventive measures and rehabilitation in reducing the risk of heart attacks. The hospital’s efforts highlight the need for increased awareness and utilization of cardiac rehab programs in India, which can significantly improve the quality of life for individuals with heart conditions. The success of the ‘Cardiac Rehab Run’ is a step towards promoting a healthier and more active lifestyle for people of all ages and backgrounds.
Alkem Laboratories has allocated INR 100 crore for the establishment of a state-of-the-art radiotherapy centre in Muzaffarpur.
Alkem Laboratories, a prominent pharmaceutical company, has made a significant investment of INR 100 crore in a new radiotherapy centre located in Muzaffarpur, Bihar. This substantial investment underscores the company’s commitment to expanding its presence in the healthcare sector and providing advanced medical facilities to patients.
The radiotherapy centre, equipped with state-of-the-art technology, aims to provide comprehensive cancer treatment services to patients in the region. By investing in this centre, Alkem Laboratories is addressing the growing need for cancer care services in India, particularly in rural and semi-urban areas where access to quality healthcare is often limited.
The new centre will offer a range of services, including radiation therapy, chemotherapy, and surgical oncology, catering to the diverse needs of cancer patients. With the establishment of this centre, Alkem Laboratories is poised to make a positive impact on the lives of patients and their families, providing them with access to world-class cancer treatment facilities.
This investment is also expected to generate employment opportunities in the region, contributing to the local economy and promoting overall development. The centre will create jobs for medical professionals, technicians, and support staff, thereby boosting the local job market and fostering growth.
Alkem Laboratories’ decision to invest in a radiotherapy centre in Muzaffarpur demonstrates the company’s focus on promoting healthcare infrastructure in tier-II and tier-III cities. By doing so, the company is bridging the gap in healthcare services between urban and rural areas, ensuring that patients in these regions have access to quality medical care.
The investment of INR 100 crore in the radiotherapy centre is a testament to Alkem Laboratories’ commitment to the healthcare sector and its dedication to improving the lives of patients. As the company continues to expand its presence in the healthcare industry, it is likely to make a significant impact on the lives of people in India, particularly in regions where access to quality healthcare is limited.
Overall, Alkem Laboratories’ investment in the new radiotherapy centre in Muzaffarpur is a positive step towards promoting healthcare infrastructure and providing advanced medical facilities to patients in the region. The company’s commitment to the healthcare sector is expected to have a lasting impact on the lives of people in India, and its efforts to expand access to quality healthcare services are commendable.
Lupin’s Pune Biotech facility receives 4 observations from the U.S. FDA.
The U.S. Food and Drug Administration (FDA) recently conducted an inspection at Lupin’s biotech facility in Pune, India. The inspection, which took place from September 8-19, 2025, was a product-specific pre-approval inspection. As a result of the inspection, the FDA issued four observations to the company.
Lupin, a generic drugmaker, has stated that it will address the observations and respond to the FDA within the stipulated timeframe. The company made this announcement in a filing on September 20, 2025. While the specific details of the observations have not been disclosed, the fact that the FDA issued four observations indicates that there are some issues that need to be resolved before the facility can receive approval for the production of certain products.
The FDA’s inspection and subsequent observations are a standard part of the regulatory process for pharmaceutical companies. The agency’s primary concern is ensuring the safety and efficacy of drugs, and it conducts regular inspections to ensure that manufacturers are complying with regulations and guidelines.
Lupin’s biotech facility in Pune is one of the company’s key manufacturing sites, and the outcome of the FDA’s inspection could have significant implications for the company’s business. If the issues raised by the FDA are not addressed, it could potentially delay or prevent the approval of certain products, which could impact the company’s revenue and growth prospects.
However, it’s worth noting that receiving observations from the FDA is not uncommon, and many companies are able to address the issues raised and receive approval for their products. Lupin has stated that it will respond to the FDA’s observations, and it’s likely that the company will work to resolve the issues as quickly as possible. The company’s ability to address the FDA’s concerns and receive approval for its products will be closely watched by investors and industry analysts in the coming months. Overall, the FDA’s inspection and observations are an important part of the regulatory process, and Lupin’s response will be critical in determining the outcome for the company.
Regulatory authorities have instructed Sun Pharma to restrict its Phase III Revefenacin study to only include patients with COPD who are currently on triple therapy.
Sun Pharmaceutical Industries Ltd, a prominent pharmaceutical company, has been instructed to limit the phase III study of Revefenacin to patients with Chronic Obstructive Pulmonary Disease (COPD) who are already receiving triple therapy. This decision comes as a regulatory measure to ensure the safe and effective evaluation of the medication.
Revefenacin is a long-acting muscarinic antagonist (LAMA) that is being developed for the treatment of COPD, a chronic and progressive lung disease that makes it difficult to breathe. The phase III study is designed to assess the efficacy and safety of Revefenacin in patients with moderate to severe COPD.
The decision to limit the study to patients receiving triple therapy is significant, as it indicates that the regulatory authorities want to evaluate the medication in a specific patient population. Triple therapy typically consists of a combination of three medications: a LAMA, a long-acting beta-agonist (LABA), and an inhaled corticosteroid (ICS). By limiting the study to patients already receiving triple therapy, the regulators aim to assess the effectiveness of Revefenacin in a real-world setting, where patients are often prescribed multiple medications to manage their condition.
The limitation of the study to triple therapy patients may also be intended to minimize the risk of adverse events and ensure the safety of participants. COPD patients often have multiple comorbidities and are prone to experiencing adverse events, so it is essential to evaluate the medication in a controlled and monitored environment.
The regulatory decision may have implications for Sun Pharma’s development plans for Revefenacin. The company may need to adjust its clinical trial design and patient recruitment strategies to comply with the new requirements. Additionally, the limitation of the study to triple therapy patients may impact the medication’s potential labeling and market positioning.
In conclusion, the instruction to limit the phase III study of Revefenacin to triple therapy COPD patients is a significant regulatory development that may impact the medication’s development and commercialization. Sun Pharma will need to adapt to the new requirements and ensure that the study is conducted in a way that meets regulatory standards and ensures patient safety. The outcome of the study will be crucial in determining the medication’s efficacy and safety in a specific patient population, and its potential to become a treatment option for COPD patients.
Alkem Foundation backs the setup of North Bihar’s biggest radiotherapy facility, located in Muzaffarpur.
Alkem Foundation, the corporate social responsibility arm of Alkem Laboratories Ltd., has invested INR 100 crores in the establishment of the Samprada Singh Memorial Radiotherapy Centre in Muzaffarpur, Bihar. This state-of-the-art facility is part of the newly inaugurated Homi Bhabha Cancer Hospital and Research Centre and has the capacity to treat 3,500-4,000 cancer patients annually, making it the largest in North Bihar and the second-largest in the state.
The centre is equipped with advanced technologies, including linear accelerators, stereotaxy, and in-house brachytherapy, and has been developed in collaboration with the Tata Memorial Centre in Mumbai. The goal of this centre is to provide world-class cancer treatment options to patients in Bihar and neighboring states, bridging the gap in cancer treatment in these regions.
According to Madhurima Singh, Executive Director of Alkem, the company has its roots in Bihar and is committed to giving back to the region. With cancer cases on the rise, the need for advanced facilities is greater than ever. The centre will not only provide treatment but also support patients and their families, creating a holistic model of care.
The partnership between Alkem Foundation and the Homi Bhabha Cancer Hospital and Research Centre builds on years of collaboration in screening and palliative care. The centre aims to provide complete and compassionate cancer care, including ethical and affordable evidence-based treatment, as well as education and research.
This initiative is part of Alkem Foundation’s existing cancer care programs, which include screening, awareness, and home-based palliative care. The foundation’s goal is to strengthen healthcare infrastructure and bridge treatment gaps in underserved regions. With the establishment of the Samprada Singh Memorial Radiotherapy Centre, Alkem Foundation is taking a significant step towards providing sustainable healthcare solutions that have a lasting impact on the community.
Aurobindo Pharma Experiences Brief Manufacturing Halt
Aurobindo Pharma, a prominent pharmaceutical company, has reported a fire incident at its wholly-owned subsidiary, APL Healthcare Ltd, located in Naidupeta, Andhra Pradesh. The fire occurred in the granulation area-10 of Unit-IV, a Special Economic Zone (SEZ) unit, due to a short circuit. The blaze spread to a nearby panel, causing partial damage to granulation area-8. Fortunately, the in-house fire hydrant team, along with external fire tenders, quickly controlled the fire, and no casualties or injuries were reported.
The incident has temporarily disrupted production, with two out of 19 production lines impacted. These lines are expected to remain non-operational for approximately two weeks. As a result, the unit’s monthly production has been reduced by about three percent. However, Aurobindo Pharma has assured that it is already working on restoring and refurbishing the affected areas and expects to resume full operations within a few weeks.
The company has emphasized its commitment to ensuring employee safety, safeguarding assets, and minimizing operational disruption. Aurobindo Pharma has implemented all necessary safety measures to protect employees and secure assets, demonstrating its proactive approach to risk management and incident response. The fire incident is not expected to have a material impact on the company’s finances or operations.
Aurobindo Pharma’s swift response to the incident and its ongoing commitment to safety and operations are testaments to its dedication to maintaining operational continuity and protecting its employees and assets. The company’s ability to quickly contain the fire and minimize damage reflects its well-established safety protocols and emergency response procedures. With the affected areas being restored and refurbished, Aurobindo Pharma is expected to bounce back to full operational capacity soon, with minimal long-term impact on its production and finances.
Teva Abandons Patent Dispute with Cipla Over Qvar Inhaler as FTC Pressures for Delisting
Teva Pharmaceutical Industries Ltd. has reached a settlement agreement to dismiss its patent-infringement lawsuit against Cipla Ltd., an Indian generic-drug maker, over proposed copies of its Qvar RediHaler asthma treatment. The agreement was approved by Judge Stanley R. Chesler in a consent order of dismissal issued in the US District Court for the District of New Jersey. The terms of the agreement were not disclosed, and neither Teva nor Cipla has commented on the matter.
Teva had filed the lawsuit in February 2024, seeking to block Cipla’s generic version of Qvar RediHaler, which is an inhalation aerosol used to treat asthma. The lawsuit alleged that Cipla’s proposed generic would infringe on Teva’s patents related to the medication. By settling the case, Teva has ended its efforts to prevent Cipla from launching a generic version of Qvar RediHaler, at least for the time being.
The agreement does not necessarily mean that Cipla will be able to launch its generic version of Qvar RediHaler immediately. The consent order of dismissal leaves the door open for either side to renew allegations in the future, suggesting that the dispute may not be fully resolved. Teva may still try to block Cipla’s generic version of Qvar RediHaler if it believes that Cipla’s product infringes on its patents.
The settlement is significant because it could impact the availability of affordable asthma treatments in the US. Qvar RediHaler is a prescription medication that is used to control and prevent symptoms of asthma. A generic version of the medication could provide a more affordable option for patients who rely on Qvar RediHaler to manage their asthma.
Overall, the settlement between Teva and Cipla highlights the complex and often contentious nature of patent disputes in the pharmaceutical industry. The agreement may have implications for patients, healthcare providers, and the pharmaceutical industry as a whole, and its impact will likely be closely watched in the coming months and years.
Sun Pharma has revamped its leadership team, and the stakes are high.
Sun Pharma, one of India’s largest pharmaceutical companies, has undergone a significant leadership transition. Dilip Shanghvi, the company’s founder and promoter, has transitioned to the role of executive chairman, while Kirti Ganorkar, who headed the India business, has taken over as managing director. Additionally, Shanghvi’s son Aalok has been appointed as chief operating officer and will oversee the company’s North America business, which is being run by Richard Ascroft, a former Takeda Pharmaceuticals executive.
The leadership changes are part of a “structured and forward-looking succession planning process” aimed at bolstering the company’s global innovative drug pipeline. Sun Pharma has been focusing on its speciality business, particularly in the US, where generic price erosion and policy uncertainties have impacted the company’s sales. The company has delivered a compound annual growth rate (CAGR) of 10% in sales between 2018-19 and 2024-25 and is expected to maintain a similar growth rate for the next three years.
The transition is significant, as it involves the company’s globally critical functions, including the India business, the US, and its long-term speciality focus. Industry experts believe that the timing of the transition is opportune, as the company is in good shape and its business is strong. The changes are aimed at making the company more professionally driven, while still maintaining the influence of the promoter family.
Aalok Shanghvi, who has been with the company for over 15 years, has been groomed to take over key responsibilities. He will oversee the North America business, which is critical for the company’s growth. Richard Ascroft, who has been appointed to run the North America business, brings significant experience in the biopharmaceutical industry. The company has also elevated Shanghvi’s daughter Vidhi to whole-time director and appointed Jayashree Satagopan as chief financial officer designate.
The transition is seen as a planned move to balance the company’s global ambitions with the grooming of the next generation of leaders. Experts believe that the company is attempting to preserve institutional memory and culture while allowing newer leadership to take over operational responsibilities. The changes are expected to help Sun Pharma compete better in the global market, protect margins, and accelerate launches of new products. Overall, the leadership transition is a significant development for Sun Pharma, as it aims to strengthen its position in the global pharmaceutical industry.
CRISIL revises outlook for Glenmark Pharma to ‘Positive’, while affirming existing ratings.
Crisil Ratings has revised the outlook on Glenmark Pharmaceuticals Limited’s long-term bank facilities to ‘Positive’ from ‘Stable’, while reaffirming the rating at ‘Crisil AA’. The short-term rating remains at ‘Crisil A1+’. This revision is based on the expectation of improved business performance and a stronger financial risk profile following Glenmark’s exclusive global licensing deal with AbbVie Inc. for its lead innovation asset, ISB 2001. The deal includes an upfront payment of $700 million, milestone payments of up to $1.225 billion, and double-digit royalties on future net sales.
In fiscal 2025, Glenmark’s revenues grew 13% to Rs. 13,321 crore, driven by a 32% growth in domestic formulations and traction in European markets. Although the US market contracted by 2.5%, revenue growth is expected to average 10-12% annually going forward, driven by growth in domestic formulations and exports to Europe and other markets. The company’s operating profits remained steady at around 18%, and profitability is expected to improve gradually, averaging 20-22% over the medium term.
Glenmark’s financial risk profile is expected to improve significantly due to the substantial upfront payout from the licensing deal. The company’s net debt increased to Rs. 797 crore as of March 31, 2025, from Rs. -427 crore as of March 31, 2024, but the annual cash accruals of around Rs. 2,000 crore are expected to be sufficient to meet debt obligations and incremental working capital requirements. The company’s unencumbered cash balance stood at Rs. 1,675 crore as of March 31, 2025, and the average bank limit utilization was 61% for the 12 months ended March 2025.
Crisil Ratings has combined the business and financial risk profiles of Glenmark and its 43 subsidiaries, which operate in the pharmaceutical segment and have significant operational linkages and a common management. The ratings agency expects an improved business and financial risk profile for Glenmark, driven by improved profitability and a stronger balance sheet position. The licensing deal with AbbVie is expected to significantly improve the company’s financial risk profile, with proceeds largely to be deployed for organic growth.
Overall, the revision in outlook to ‘Positive’ reflects Crisil Ratings’ expectation of improved business performance and a stronger financial risk profile for Glenmark, driven by the licensing deal with AbbVie and the company’s strong operating performance. The ratings agency expects Glenmark’s revenue growth to average 10-12% annually going forward, driven by growth in domestic formulations and exports to Europe and other markets. The company’s financial risk profile is expected to improve significantly due to the substantial upfront payout from the licensing deal, and the ratings agency expects an improved business and financial risk profile for Glenmark over the medium term.
A minor blaze broke out in the granulation section of Aurobindo Pharma’s Unit IV, specifically area-10, according to the company.
Aurobindo Pharma is a pharmaceutical company that focuses on the research, development, manufacturing, and marketing of active pharmaceutical ingredients and generic pharmaceuticals. The company’s products can be categorized into two main families: generic drugs and active pharmaceutical ingredients. The generic drugs offered by Aurobindo Pharma are used to treat a wide range of diseases, including neurological, cardiovascular, viral, gastroenterological, ophthalmologic, and chronic diseases.
As of March 2018, Aurobindo Pharma operated a total of 23 production sites across three countries: India, the United States, and Brazil. The majority of these production sites, 19, are located in India, while the remaining four are split between the United States, with three sites, and Brazil, with one site. This global presence enables the company to manufacture and supply its products to various markets around the world.
In terms of its sales, Aurobindo Pharma generates revenue from several geographic regions. The company’s net sales are distributed as follows: 12% from India, 46.5% from the United States, 31.2% from Europe, and 10.3% from other regions. This indicates that the United States is the company’s largest market, accounting for nearly half of its total sales. Europe is also a significant market for Aurobindo Pharma, contributing over 30% to the company’s net sales.
Overall, Aurobindo Pharma is a major player in the pharmaceutical industry, with a diverse portfolio of products and a global presence. The company’s focus on generic drugs and active pharmaceutical ingredients has enabled it to establish a strong position in the market, with a significant presence in several geographic regions. With its extensive network of production sites and diverse sales distribution, Aurobindo Pharma is well-positioned to continue growing and expanding its operations in the future. The company’s commitment to research, development, and manufacturing has enabled it to become a leading provider of affordable and high-quality pharmaceuticals to patients around the world.
Lupin receives US FDA nod for generic Lenalidomide Capsules, reports The Indian EYE
Lupin Ltd, a global pharmaceutical company, has received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules. The approved capsules are available in strengths of 2.5 mg to 25 mg and are used to treat adult patients with Multiple Myeloma, a type of blood cancer, in combination with dexamethasone. The capsules will be manufactured at Lupin’s Pithampur facility in India.
This approval is significant, as the estimated annual sales of Lenalidomide Capsules in the United States are around $7,511 million. Lupin is a leading player in the pharmaceutical industry, with a strong presence in over 100 markets worldwide. The company specializes in a range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
With a dedicated workforce of over 24,000 personnel, Lupin has a strong position in both India and the US, excelling in multiple therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. The company has 15 state-of-the-art manufacturing sites and seven research centers across the world, demonstrating its commitment to innovation and quality.
The approval of Lenalidomide Capsules is a testament to Lupin’s capabilities in developing and manufacturing complex generic products. The company’s strong research and development capabilities, combined with its global manufacturing footprint, enable it to bring high-quality products to patients worldwide. With this approval, Lupin is well-positioned to capitalize on the growing demand for generic pharmaceuticals in the US market.
Overall, the approval of Lenalidomide Capsules is a significant milestone for Lupin, demonstrating its ability to develop and manufacture complex generic products that meet the stringent regulatory standards of the US FDA. The company’s commitment to innovation, quality, and patient care is evident in its continued investments in research and development, manufacturing, and global expansion.
Pfizer and Roivant’s novel therapy demonstrates significant patient-centered advantages in treating a rare inflammatory disorder, according to recent findings reported by BioSpace.
A recent study has shown that a therapy developed by Roivant Sciences and Pfizer has demonstrated a “patient-centered benefit” in treating a rare inflammatory condition. The condition, known as sjögren-Larsson syndrome, is a genetic disorder that affects the skin, eyes, and brain, causing symptoms such as dry skin, itching, and vision problems.
The therapy, which is still in the experimental stages, uses a novel approach to target the underlying causes of the condition. According to the study, the treatment has shown significant improvements in patient symptoms, including reduced itching and improved skin health.
The study’s findings are significant, as current treatments for sjögren-Larsson syndrome are limited and often focus on managing symptoms rather than addressing the underlying causes of the condition. The new therapy, if approved, could provide a much-needed treatment option for patients with this rare and debilitating condition.
Roivant Sciences, a biopharmaceutical company, and Pfizer, a global pharmaceutical giant, have been collaborating on the development of the therapy. The two companies have been working together to advance the treatment through clinical trials, with the goal of bringing it to market as soon as possible.
The patient-centered benefit of the therapy is a key aspect of its development. The treatment is designed to improve the quality of life for patients with sjögren-Larsson syndrome, rather than just managing their symptoms. By targeting the underlying causes of the condition, the therapy has the potential to provide long-term benefits and improve patient outcomes.
The study’s results are a promising step forward in the development of treatments for rare inflammatory conditions. With only a limited number of treatment options available, patients with these conditions often face significant challenges in managing their symptoms and improving their quality of life. The new therapy, if approved, could provide a much-needed option for patients with sjögren-Larsson syndrome and potentially pave the way for the development of treatments for other rare inflammatory conditions.
Overall, the study’s findings demonstrate the potential of the Roivant and Pfizer therapy to provide a patient-centered benefit for individuals with sjögren-Larsson syndrome. As the treatment continues to move through clinical trials, it is likely that patients and clinicians will be watching closely to see if it will become a viable treatment option for this rare and debilitating condition.
Muzaffarpur set to receive a Rs 100 crore radiotherapy center: Rediff Money News
A new radiotherapy center is being developed in Muzaffarpur, Bihar, with an investment of Rs 100 crore by Alkem Laboratories. The center, named Samprada Singh Memorial Radiotherapy Centre, will be part of the Homi Bhabha Cancer Hospital and Research Centre (HBCHRC), which was recently inaugurated by Prime Minister Narendra Modi. The radiotherapy center aims to treat 3,500-4,000 patients every year, addressing the growing need for cancer treatment facilities in the region.
The center is named after Alkem’s late founder, who hailed from Bihar, and is a testament to the company’s commitment to giving back to the community. According to Alkem’s Executive Director, Madhurima Singh, the company has its roots in Bihar, and it is meaningful for them to contribute to the region, especially with the rising cases of cancer. The partnership between Alkem and HBCHRC builds on years of collaboration in screening and palliative care, and the new center will provide complete and compassionate cancer care to patients in Bihar and neighboring states.
The development of the radiotherapy center is a significant step towards bridging the gap in cancer treatment in the region. With the rising incidence of cancer, there is a growing need for world-class facilities that can provide comprehensive care to patients. The center will be equipped with state-of-the-art technology and will provide treatment to patients from Bihar and neighboring states. The partnership between Alkem and HBCHRC is expected to have a significant impact on the healthcare landscape of the region, providing much-needed access to cancer treatment and care.
The investment of Rs 100 crore by Alkem Laboratories is a significant commitment to the development of the radiotherapy center. The company’s contribution will help to establish a world-class facility that will provide treatment to thousands of patients every year. The center will be a major boost to the healthcare infrastructure of the region, and will help to address the growing need for cancer treatment facilities. Overall, the development of the Samprada Singh Memorial Radiotherapy Centre is a significant step towards improving cancer care in Bihar and neighboring states.
US FDA Grants Approval to Lupin for Generic Version of Lenalidomide Capsules
Lupin Ltd, a global pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules. The capsules, which will be manufactured at Lupin’s Pithampur facility in India, are indicated for the treatment of adult patients with multiple myeloma, transfusion-dependent anemia, and other related conditions. The FDA approval is a significant milestone for Lupin, as Lenalidomide Capsules had estimated annual sales of $7,511 million in the United States.
Lupin Ltd is a Mumbai-based company with a strong presence in over 100 markets worldwide. The company specializes in a range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has a significant presence in India and the US, with a focus on multiple therapy areas such as respiratory, cardiovascular, and women’s health.
The company has a robust infrastructure, with 15 state-of-the-art manufacturing sites and seven research centers globally. Lupin also has a dedicated workforce of over 24,000 professionals and several subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. This is not the first FDA approval for Lupin, as the company received approval for its generic ‘Minzoya’ tablets last year. The Minzoya tablets are used to prevent pregnancy and are a generic equivalent of Balcoltra tablets.
The FDA approval for Lenalidomide Capsules is a testament to Lupin’s commitment to providing high-quality and affordable pharmaceutical products to patients worldwide. The company’s Pithampur facility in India, where the capsules will be manufactured, is a key part of Lupin’s global manufacturing network. With this approval, Lupin is well-positioned to expand its presence in the US market and provide patients with access to affordable and effective treatments for multiple myeloma and other related conditions. Overall, the FDA approval is a significant achievement for Lupin and reflects the company’s ongoing efforts to develop and market high-quality pharmaceutical products.
Piramal Pharma Solutions enhances its formulation capabilities with the installation of a new Korsch XM-12 Bilayer Tablet Press at its UK-based Morpeth facility.
Piramal Pharma Solutions has enhanced its capabilities with the addition of the Korsch XM-12 bilayer tablet press at its Morpeth facility. This strategic investment reinforces the company’s commitment to advancing drug delivery, quality, and patient-centricity. The XM-12 is designed for both single-layer and bilayer production, featuring advanced sanitary fittings, a special product chute for high potency APIs, and rapid changeover turrets. The press enables the facility to produce premium tablets at scale with accuracy, speed, and flexibility.
To ensure the safe and efficient operation of the XM-12, Piramal Pharma Solutions has implemented comprehensive training protocols for its scientists, operators, and maintenance teams. The training will be tailored to meet the unique requirements of each role within the Formulation Development Team, covering both bilayer and single-layer modes, changeovers, cleaning, and containment testing. The XM-12 is equipped with built-in technology that maintains consistent precision output with minimal operator interaction once critical settings are established.
The addition of the Korsch XM-12 is a significant milestone for Piramal Pharma Solutions, demonstrating its commitment to delivering innovative therapies to patients worldwide. As a Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions offers end-to-end development and manufacturing solutions across the drug life cycle, serving customers through a globally integrated network of facilities in North America, Europe, and Asia.
Piramal Pharma Solutions is part of Piramal Pharma Limited, a company that offers a portfolio of differentiated products and services through its global development and manufacturing facilities and distribution network. Piramal Pharma Limited includes Piramal Pharma Solutions, Piramal Critical Care, and Piramal Consumer Healthcare, among other businesses. The company has a strategic minority investment in Yapan Bio Private Limited, which operates in the biologics and bio-therapeutics segments.
The Korsch XM-12 bilayer tablet press is a key addition to Piramal Pharma Solutions’ capabilities, enabling the company to produce high-quality tablets with precision and efficiency. With its advanced features and comprehensive training protocols, the XM-12 will help Piramal Pharma Solutions deliver innovative therapies to more patients, ultimately reducing the burden of disease worldwide. The company’s commitment to quality, safety, and patient-centricity is evident in its strategic investments and partnerships, solidifying its position as a leading CDMO in the pharmaceutical industry.
Apollo launches specialized cancer facility exclusively for women in Delhi.
Apollo Hospitals Enterprise Ltd (AHEL) has launched Apollo Athenaa, Asia’s first dedicated cancer centre for women, located in Defence Colony, New Delhi. The centre was inaugurated by Delhi Chief Minister Rekha Gupta, in the presence of Dr Prathap C Reddy, Founder-Chairman of Apollo Hospitals Group, and other dignitaries. The launch of this centre is a significant step towards addressing the growing incidence of cancer among women in India.
According to recent studies, more women than men are being diagnosed with cancer, with breast and cervical cancers being the most common types among Indian women. The Indian Council of Medical Research’s (ICMR) National Cancer Registry Programme (NCRP) has reported that these two types of cancer account for the highest incidence among women. The GLOBOCAN 2022 estimates also reveal that nearly 54% of cancer incidence among women in India is attributed to cancers that majorly affect women, including breast and cervical cancers.
The Apollo Athenaa centre aims to provide a comprehensive and sensitive approach to cancer care for women, ensuring dignity, security, and privacy for every patient. The centre’s launch is also seen as a milestone in cancer care, complementing the national health mission to enhance prevention, early detection, treatment, and patient care nationwide. The Government of India has introduced robust policies and strategic interventions to address the rising incidence of cancer, and the Apollo Athenaa centre is expected to play a significant role in this effort.
The inauguration of the centre was attended by several dignitaries, including Bansuri Swaraj, Member of Parliament, who highlighted the government’s commitment to women’s health and cancer care. The centre’s launch is a transformative initiative that sets a global benchmark in women-centric cancer care, and it is expected to make a significant impact in the lives of women affected by cancer. With the establishment of Apollo Athenaa, Apollo Hospitals Enterprise Ltd has reinforced its commitment to providing innovative and patient-centric healthcare services, particularly in the area of cancer care for women.
Zydus Lifesciences introduces generic pet medications for felines and canines.
ZyVet Animal Health, a subsidiary of Zydus Pharmaceuticals, has introduced two FDA-approved generic medicines for animals in the US market. The first medicine, Phenylpropanolamine hydrochloride tablets, is used to treat urinary incontinence in dogs, a condition commonly affecting spayed females and older dogs. This medication works by addressing urethral sphincter hypotonus, a condition that leads to urinary incontinence. With this launch, veterinarians now have an affordable alternative for long-term management of the disorder.
The second medicine, Furosemide tablets, is used to manage congestive heart failure and chronic fluid retention in dogs and cats. Furosemide is a commonly prescribed diuretic that reduces edema and pulmonary congestion caused by cardiac, renal, or systemic disease. The approval of these generic medicines is expected to provide veterinarians with cost-effective treatment options for their patients.
The launch of these generic medicines comes as Zydus Lifesciences Ltd reported a net profit of ₹1,467 Crore for the quarter ended June 2025, a 3.3% increase from the previous corresponding period. The company’s revenue also registered a 6% year-over-year growth at ₹6,574 Crore, with an EBITDA of ₹2,089 Crore for the quarter.
The introduction of these generic medicines is a significant development for the animal health industry, as it provides veterinarians with affordable treatment options for common conditions affecting dogs and cats. The approval of these medicines by the FDA ensures their safety and efficacy, giving pet owners and veterinarians confidence in their use. With the growing demand for affordable and effective animal health treatments, ZyVet Animal Health’s launch of these generic medicines is a positive step forward for the industry.
Amgen, Biocon, and Samsung Biologics make investments in pharmaceutical facilities in the US.
International pharmaceutical companies are increasing their investments in the US to be closer to key markets and mitigate the risks of global trade and supply chain disruptions. Despite pharmaceutical imports being exempt from US tariffs, President Trump’s threats to impose tariffs as high as 250% have created uncertainty for the industry. The Supreme Court is currently evaluating the legality of the administration’s global tariffs, which may impact the industry.
Several companies have recently announced significant investments in the US. Samsung Biologics, a South Korean-based company, has signed a $1.3 billion contract manufacturing deal with a US pharmaceutical company. This deal is the second-largest since the company’s founding in 2011 and adds to its growing number of production contracts with companies outside of South Korea. Samsung Biologics has also opened a laboratory in San Francisco and is considering further US expansion opportunities.
Amgen, a US-based drugmaker, is investing over $600 million to build a science and innovation center at its global headquarters in Thousand Oaks, California. The center will bring together experts to accelerate research and development of next-generation medicines, creating hundreds of US jobs. This investment builds on Amgen’s previous investments, including a $900 million factory expansion in Central Ohio and a $1 billion manufacturing plant in North Carolina.
Biocon, an India-based company, has opened its first US factory in Cranbury, New Jersey, expanding its manufacturing footprint in the country. The company acquired the oral medications factory from Eywa Pharma in 2023 and has invested over $30 million to update the facility, increasing its production capacity to 2 billion tablets per year. The move brings Biocon closer to patients, healthcare providers, and partners across the US and other important markets.
These investments demonstrate the pharmaceutical industry’s efforts to adapt to changing global trade dynamics and supply chain complexities. By investing in the US, companies can reduce their reliance on international supply chains and mitigate the risks associated with tariffs and trade uncertainty. The investments also highlight the importance of the US market for pharmaceutical companies, with many seeking to establish a presence in the country to be closer to key markets and customers.
Meha Patel, Vice Chairperson of the Zydus Foundation, has been appointed as a member of the Confederation of Indian Industry’s National Committee on Art and Culture for the term 2025-26.
Meha Patel, the Vice Chairperson of the Zydus Foundation, has been appointed as a member of the Confederation of Indian Industry (CII) National Committee on Art & Culture for the year 2025-26. This appointment is a significant recognition of Meha Patel’s contributions to the field of art and culture, and her expertise in promoting and preserving India’s rich cultural heritage.
The CII National Committee on Art & Culture is a prestigious platform that brings together industry leaders, artists, and cultural experts to promote and develop India’s art and culture sector. The committee’s objectives include promoting Indian art and culture globally, supporting the development of cultural infrastructure, and fostering collaborations between industry, government, and cultural institutions.
As a member of the CII National Committee on Art & Culture, Meha Patel will play a key role in shaping the committee’s policies and initiatives, and will work closely with other members to promote India’s art and culture sector. Her appointment is expected to bring a new perspective and energy to the committee, and will help to further the Zydus Foundation’s mission of promoting social and cultural development.
The Zydus Foundation is a non-profit organization that works towards promoting social and cultural development, and has been involved in various initiatives to promote art, culture, and education. Meha Patel’s appointment to the CII National Committee on Art & Culture is a testament to the foundation’s commitment to promoting India’s rich cultural heritage, and its efforts to make a positive impact on society.
Meha Patel’s appointment is also a recognition of her individual contributions to the field of art and culture. As a prominent social and cultural figure, she has been involved in various initiatives to promote Indian art and culture, and has worked tirelessly to support the development of cultural infrastructure in India. Her expertise and passion for art and culture make her an ideal candidate for the CII National Committee on Art & Culture, and her appointment is expected to be a significant asset to the committee.
Overall, Meha Patel’s appointment as a member of the CII National Committee on Art & Culture is a significant recognition of her contributions to the field of art and culture, and her expertise in promoting and preserving India’s rich cultural heritage. Her appointment is expected to bring a new perspective and energy to the committee, and will help to further the Zydus Foundation’s mission of promoting social and cultural development.
Biocon Foundation has initiated the construction of a new school building in Kodamballi, which aims to provide educational support to approximately 250 students.
On September 15, 2025, the Biocon Foundation, the corporate social responsibility arm of the Biocon Group, launched the construction of a new Government High School building in Kodamballi, Channapatna Taluk, Karnataka. The school currently serves over 250 children from 23 nearby villages. The groundbreaking ceremony was attended by Dr. C.N. Manjunath, Member of Parliament, Shri C.P. Yogeshwara, MLA of Channapatna, and other senior representatives of the Biocon Group.
The new building will be a two-story structure with 10 large classrooms and a sanitation complex with separate facilities for boys and girls. This initiative is part of the Biocon Foundation’s commitment to enhancing access to quality education through infrastructure development. The foundation believes that education is the cornerstone of empowerment and aims to create safe, inclusive, and inspiring spaces for children to learn and thrive.
The project has received support from local government officials, including Dr. C.N. Manjunath, who praised the Biocon Foundation’s efforts in strengthening government school infrastructure. Shri C.P. Yogeshwara, MLA of Channapatna, also expressed his gratitude to the Biocon Group for their initiative, which he hopes will inspire children to study well and aspire to become scientists.
The Biocon Foundation has previously invested in upgrading rural education infrastructure, including classrooms, science labs, libraries, and sanitation facilities across several government schools. This project marks the foundation’s first initiative in Channapatna under the Greater Bengaluru Authority (GBA) and reflects its continued support for improving rural education.
The construction of the new school building is expected to provide better facilities and a more conducive learning environment for the students. The Biocon Foundation’s commitment to education is aligned with the government’s focus on improving the infrastructure of rural schools. By investing in education, the foundation is not only supporting the state’s vision of inclusive and equitable learning but also creating opportunities for children in rural areas to aspire for a brighter future.
Teamwork Financial Advisors LLC increases its stake in Pfizer Inc., ticker symbol $PFE, according to MarketBeat.
Teamwork Financial Advisors LLC has increased its stake in Pfizer Inc. ($PFE), a multinational pharmaceutical corporation. According to recent filings, Teamwork Financial Advisors LLC has raised its holdings in Pfizer, indicating a growing confidence in the company’s prospects.
Pfizer Inc. is one of the world’s largest pharmaceutical companies, with a diverse portfolio of products and a strong track record of innovation. The company has a market capitalization of over $500 billion and is a component of the S&P 500 index. Pfizer’s product lineup includes a range of prescription medicines, vaccines, and consumer healthcare products, such as Advil, ChapStick, and Centrum.
The decision by Teamwork Financial Advisors LLC to increase its holdings in Pfizer may be attributed to several factors. Firstly, Pfizer has a strong pipeline of new products and therapies, including several high-profile treatments for rare diseases and cancer. The company has also been investing heavily in research and development, with a focus on emerging technologies such as gene editing and mRNA-based therapies.
Additionally, Pfizer has a solid financial track record, with a history of generating strong cash flows and paying consistent dividends to its shareholders. The company’s dividend yield is currently around 3.5%, making it an attractive option for income-seeking investors.
In recent years, Pfizer has also been actively involved in mergers and acquisitions, expanding its portfolio through strategic deals. The company’s acquisition of Hospira in 2015, for example, added a range of generic and injectable products to its lineup. More recently, Pfizer announced a deal to acquire Array Biopharma, a biotech company focused on developing treatments for cancer and other diseases.
The increased holdings by Teamwork Financial Advisors LLC may also reflect the company’s relatively low valuation compared to its peers. Pfizer’s price-to-earnings ratio is currently around 14, which is lower than many of its competitors in the pharmaceutical industry.
Overall, the decision by Teamwork Financial Advisors LLC to raise its holdings in Pfizer Inc. suggests a positive outlook for the company’s future prospects. With its strong product pipeline, solid financials, and attractive valuation, Pfizer remains a compelling investment opportunity for many investors. As the pharmaceutical industry continues to evolve and grow, companies like Pfizer are well-positioned to capitalize on emerging trends and technologies, making them an attractive option for long-term investors.
Apollo Hospitals has allocated ₹5.73 billion for the development of a state-of-the-art oncology centre in Gurugram.
The global cancer burden is escalating, with the World Health Organization (WHO) reporting nearly 10 million deaths in 2020. India, with a population of over 1.4 billion, is projected to experience a surge in cancer cases by 2025 due to urbanization, lifestyle shifts, and aging populations. To address this growing healthcare demand, Apollo Hospitals has invested 5,730 million rupees in a comprehensive oncology facility in Gurugram, a satellite city of Delhi.
The strategic rationale behind this investment is to bridge the critical infrastructure gap in oncology care in Gurugram, which faces systemic infrastructure deficits, including poor drainage, air pollution, and traffic chaos. The new facility will be equipped with WHO-endorsed screening and treatment protocols, including advanced therapies like immunotherapies. By integrating these therapies into its services, Apollo positions itself to meet the evolving needs of a patient base that increasingly demands precision medicine.
The financial viability of Apollo’s investment hinges on the scalability of cancer care demand in Gurugram and the hospital’s ability to navigate local infrastructure limitations. While specific data on Gurugram’s cancer prevalence is limited, broader trends in India suggest a robust market. The WHO estimates that cancer cases in low- and middle-income countries will rise sharply in the coming decade due to aging populations and lifestyle changes.
However, the city’s infrastructure challenges, such as monsoon-related traffic gridlocks and air pollution, could strain patient access and operational efficiency. Apollo’s strategic location in Gurugram and ability to leverage telemedicine and mobile diagnostics could enhance outreach to underserved communities. The hospital’s financial model must also account for the high costs of oncology care, and securing partnerships with insurance providers and government subsidy programs will be crucial in ensuring patient access and revenue sustainability.
In conclusion, Apollo Hospitals’ investment in Gurugram reflects a nuanced understanding of India’s healthcare landscape. By addressing a critical infrastructure gap in a high-growth urban center, the hospital aligns with global health priorities and taps into a market poised for expansion. While challenges persist, Apollo’s integration of WHO-endorsed protocols and digital health tools positions it to mitigate risks and capture long-term value. As cancer prevalence continues to rise, investments like these will define the future of oncology care in India, and Apollo’s role as a leader in this transformation.
India sees significant decline in outbound foreign direct investment, falling to $2.1 billion, with Zydus Medtech investing $232.6 million.
India’s outward foreign direct investment (FDI) has seen a significant decline in August, dropping to $2.1 billion from $3.4 billion in the same month last year. This represents a 38% decrease year-over-year. Compared to the previous month, the decline is even more pronounced, with a 49% drop from $4.1 billion in July.
The Reserve Bank of India (RBI) data reveals that the decline in outward FDI is attributed to a decrease in all three components: equity, loans, and guarantees. Equity investment fell to $939.6 million in August, down from $1.2 billion last year and $1.7 billion in July. Debt, or loans, also decreased to $510.3 million in August, compared to $682.1 million last year and $737.2 million in July.
Guarantees for overseas units saw the sharpest decline, moderating to $647.8 million in August from $1.5 billion last year and $1.64 billion in July. This represents a 57% decrease year-over-year and a 61% decrease compared to the previous month.
Despite the overall decline, some Indian companies continued to make significant investments abroad. Tata Steel committed $355 million in equity to its Singapore-based subsidiary, while Zydus Medtech invested $232.6 million in its French subsidiary, comprising $230.3 million in guarantees and $2.3 million in equity. Samvardhana Motherson International also invested $230.3 million in debt in a joint venture in the Netherlands.
The decline in India’s outward FDI may be indicative of a cautious approach by Indian companies in the face of global economic uncertainty. However, the continued investment by companies like Tata Steel, Zydus Medtech, and Samvardhana Motherson International suggests that Indian businesses remain committed to expanding their global presence. Overall, the data suggests that Indian companies are adopting a more measured approach to foreign investment, with a focus on strategic and targeted investments rather than broad-based expansion.
CDSCO Panel Denies Zydus’ Request to Waive Phase III Clinical Trial Due to Inadequate Efficacy and Safety Information.
A Central Drugs Standard Control Organisation (CDSCO) panel has rejected Zydus’ request for a phase III clinical trial (CT) waiver for their proposed COVID-19 vaccine. The decision was based on the panel’s findings that the available data on the vaccine’s efficacy and safety were insufficient.
The CDSCO panel reviewed the company’s application, which included data from phase I and II trials, as well as animal studies. However, the panel felt that the data did not provide adequate evidence of the vaccine’s efficacy and safety in humans. Specifically, the panel noted that the phase II trial had a small sample size and was not adequately powered to determine the vaccine’s efficacy.
The panel also raised concerns about the vaccine’s safety profile, citing a lack of long-term follow-up data and inadequate reporting of adverse events. Additionally, the panel noted that the company had not provided sufficient data on the vaccine’s immunogenicity, which is the ability of the vaccine to induce an immune response.
The CDSCO panel’s decision is a setback for Zydus, which had hoped to accelerate the development of its COVID-19 vaccine. The company will now need to conduct a phase III clinical trial, which will require a larger sample size and more comprehensive data on the vaccine’s efficacy and safety.
The rejection of Zydus’ waiver request highlights the importance of rigorous clinical trials in ensuring the safety and efficacy of COVID-19 vaccines. The Indian government has been pushing for the rapid development of indigenous COVID-19 vaccines, but the CDSCO panel’s decision demonstrates that regulatory agencies will prioritize the safety and efficacy of these vaccines over haste.
The CDSCO panel’s decision also underscores the challenges faced by Indian pharmaceutical companies in developing COVID-19 vaccines. While several Indian companies have announced plans to develop COVID-19 vaccines, few have progressed to advanced stages of clinical trials. The rejection of Zydus’ waiver request serves as a reminder that the development of COVID-19 vaccines is a complex and time-consuming process that requires careful evaluation of efficacy and safety data.
Prominent pharmaceutical companies such as Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, and Torrent Pharma are navigating the complexities of the pharma value chain.
The pharmaceutical industry is complex, with various segments such as innovator products, generics, branded generics, and API. Indian companies are making headway globally, and understanding the industry’s intricacies is crucial for those seeking opportunities. Innovator companies undertake significant risks, with only 8 out of 100 molecules crossing the finish line, and patent protection is the incentive for undertaking this risk. Roche, a leading innovator, reported a 30% PAT margin in FY24, with R&D expenses at 20% of sales.
Indian pharma is sustained by generics, but companies like Sun Pharma and Glenmark Pharma are making modest beginnings in innovation. Sun Pharma’s innovative medicine segment has 11 products, including Ilumya, which reported sales of $680 million in FY25. Glenmark Pharma’s Ichnos Glenmark Innovation (IGI) recently entered a licensing agreement with AbbVie for its ISB 2001, receiving $700 million in milestone payments.
The generics business is dependent on the level of competition, with prices declining sharply as the number of competitors increases. Branded generics, however, offer higher value, with companies like Mankind Pharma and Torrent Pharma generating significant revenues from their branded portfolios. Complex generics, such as Lupin’s generic Spiriva, hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
Biosimilars are a growing segment, with companies like Biocon developing portfolios. The biosimilar approval process involves clinical trials, increasing the cost of development to $200-300 million. CRDMO (contract research and development and manufacturing outsourcing) is another emerging segment, with companies like Divi’s Labs and Anthem Biosciences securing a portion of the innovators’ drug development process.
The API business is largely commoditized, with prices dependent on tonnage. However, high-potent APIs and complex manufacturing processes can fetch higher margins. India has focused on API development with its PLI schemes, and companies like Aurobindo Pharma are establishing API facilities.
For investors, a strong branded generic base supplemented by a wide innovator portfolio is essential for trail-blazing growth. Complex generics and CRDMO are emerging sectors, with China+1 and the US Biosecure Act providing tailwinds. The right mix of business segments and prospects is crucial for growth, and understanding the industry’s intricacies is essential for those seeking opportunities in the pharmaceutical sector.
Key takeaways include:
* Innovator companies undertake significant risks, but patent protection provides an incentive.
* Indian pharma is sustained by generics, but companies are making modest beginnings in innovation.
* Branded generics offer higher value, with companies generating significant revenues from their branded portfolios.
* Complex generics hold a value proposition in regulated markets, with strong revenue streams and above-average margins.
* Biosimilars are a growing segment, with companies developing portfolios.
* CRDMO is an emerging segment, with companies securing a portion of the innovators’ drug development process.
* The API business is largely commoditized, but high-potent APIs and complex manufacturing processes can fetch higher margins.
Biocon launches its inaugural US-based manufacturing plant in Cranbury.
On September 12, 2025, Biocon Limited, a global biopharmaceutical company from India, announced the inauguration of its first US manufacturing facility in Cranbury, New Jersey. The facility, acquired from Eywa Pharma Inc. in 2023, has undergone a $30 million investment to become a state-of-the-art plant with an annual production capacity of 2 billion tablets. This strategic move enables Biocon to diversify its manufacturing base, strengthen its supply chain, and expand its global footprint.
The Cranbury facility will play a crucial role in Biocon’s US operations, providing faster access to essential therapies, enhanced supply reliability, and a stronger connection with partners and healthcare providers. According to Abhijit Zutshi, Chief Commercial Officer of Biocon Limited, the company’s decision to expand in the US is based on its strategy to create access to life-saving drugs, particularly in light of the COVID-19 pandemic.
The inauguration ceremony was attended by Governor Phil Murphy, who served as the guest of honor, along with Biocon’s Chairperson, Kiran Mazumdar-Shaw, and other dignitaries. Mazumdar-Shaw emphasized that the facility marks a new chapter in Biocon’s journey of global expansion and reaffirms the company’s purpose to serve patients worldwide. Governor Murphy praised Biocon’s decision to open its first US manufacturing facility in New Jersey, highlighting the state’s reputation as a hub for the pharmaceutical industry.
The Cranbury facility currently employs approximately 60 people, with plans to grow to around 80-85 employees in the next few months. Biocon’s CEO, Siddharth Mittal, expressed his gratitude to Governor Murphy and Mazumdar-Shaw for attending the inauguration, stating that the facility brings the company closer to patients, healthcare providers, and partners in the US market. The proximity of the facility will enable Biocon to deliver high-quality medicines more efficiently, ensuring supply chain resilience and advancing its mission to expand access to affordable therapies worldwide.
The establishment of Biocon’s first US manufacturing facility in New Jersey is a significant milestone for the company, marking its commitment to fostering innovation, creating job opportunities, and strengthening the US healthcare ecosystem. With its strategic location and state-of-the-art infrastructure, the facility is poised to play a vital role in Biocon’s global expansion and its mission to provide high-quality medicines to patients across the globe.
Facilitates prompt heart transplantation services at Apollo Seshadripuram
In a groundbreaking achievement, Apollo Hospitals in Bengaluru, in collaboration with the Bangalore Metro Rail Corporation Limited (BMRCL) and the state health authority, Jeeva Sarthakathe (JSK), successfully transported a donated human heart through the city’s Metro rail network. The heart was harvested from a donor at a private hospital in Yeshwanthpur and needed to be transported quickly to Apollo Hospitals, Seshadripuram, for a critical heart transplant surgery.
To avoid Bengaluru’s notorious traffic congestion, the heart was shifted using the Metro rail network from Goraguntepalya Metro Station to Mantri Square Metro Station, taking just 18 minutes to complete the journey. This feat was made possible through seamless coordination between BMRCL, the city police, and the hospital’s transplant team, ensuring that the heart was moved within the medically critical “golden window.”
The recipient of the heart transplant was a 33-year-old doctor from Assam who had been suffering from heart failure for a long time. He had been waiting for a heart transplant since 2023 but was unable to find a suitable donor. Thanks to the efforts of JSK and the awareness of organ donation, the doctor was finally able to receive a new heart and a second chance at life.
The transplant surgery was successfully completed by a team of experts from Apollo Hospitals, and the patient is now recovering. The hospital’s senior cardiac surgeon praised the cooperation extended by BMRCL and JSK, stating that every minute is precious when it comes to organ transplants, and their efforts ensured that the heart reached safely and quickly, saving a patient’s life.
This initiative sets a precedent for future organ transport protocols in urban India and marks another milestone in Bengaluru’s efforts towards strengthening its green corridor and rapid organ transport system. The hospital’s spokesperson expressed gratitude to the donor family, BMRCL, and JSK for their roles in making the mission successful, highlighting the importance of seamless coordination and teamwork in saving lives.
India’s Vaccine Development Gets Boost with Indigenous Efforts, AI-Powered ICMR, Gennova, and Zydus Led Initiatives
The Indian Council of Medical Research (ICMR) has been driving efforts to indigenize vaccine development in India, leveraging advanced technologies such as artificial intelligence (AI). This initiative aims to enhance the country’s self-reliance in vaccine production and distribution. Several Indian companies, including Gennova and Zydus, are at the forefront of this endeavor, utilizing AI and other cutting-edge technologies to accelerate vaccine development.
Gennova Biopharmaceuticals, a Pune-based company, has been working on an mRNA-based vaccine for COVID-19. The company has employed AI algorithms to optimize the vaccine’s design, development, and testing. This approach has enabled Gennova to rapidly identify potential vaccine candidates and predict their efficacy. Moreover, AI-powered analytics have facilitated the analysis of large datasets, allowing researchers to better understand the vaccine’s behavior and make data-driven decisions.
Zydus Cadila, another Indian pharmaceutical company, has also been actively involved in vaccine development. The company has developed a DNA-based vaccine for COVID-19, which has shown promising results in clinical trials. Zydus has utilized AI and machine learning algorithms to improve the vaccine’s stability, potency, and scalability. Additionally, the company has leveraged AI-powered predictive modeling to forecast vaccine demand and optimize distribution logistics.
The ICMR has been providing critical support to these companies, offering access to advanced research facilities, funding, and expertise. The council has also been collaborating with international organizations to stay abreast of the latest developments in vaccine technology and AI applications. By harnessing the power of AI and other advanced technologies, Indian companies are poised to make significant contributions to the global vaccine landscape.
The indigenization of vaccine development in India has far-reaching implications for the country’s healthcare sector. By reducing dependence on foreign vaccine imports, India can ensure a more stable and reliable supply of vaccines, particularly during times of crisis. Furthermore, the development of homegrown vaccines can lead to cost savings, improved accessibility, and enhanced public health outcomes. As India continues to invest in AI-driven vaccine development, the country is likely to emerge as a major player in the global vaccine market, with the potential to address pressing public health challenges both domestically and internationally.
Pharmaceutical and healthcare industries excel in the BT500 2025 rankings.
The Indian healthcare sector has experienced a significant surge in profit, with a 29% rise in profit after tax (PAT) in the fiscal year 2025. This makes it the second-fastest growing sector in the country, surpassed only by the non-ferrous metals sector. The impressive growth of the healthcare sector has caught the attention of top private equity (PE) and venture capital funds worldwide, which are now competing to invest in this rapidly expanding market.
Over the past five years, the healthcare sector has received a substantial $13 billion in PE funding, accounting for 8-9% of the total PE activity in India. This represents a significant increase from 2018, when the sector accounted for only 2% of the total PE activity. The influx of investments has contributed to the sector’s remarkable growth, with major players such as Sun Pharma and Apollo Hospitals reporting substantial profits.
Sun Pharma, for instance, has reported a billion-dollar-plus PAT, while Apollo Hospitals has seen growing margins. The healthcare sector has emerged as a vital profit engine for India Inc., with its growth outpacing many other sectors. The sector’s attractiveness to investors can be attributed to India’s large and growing population, increasing healthcare needs, and the government’s efforts to improve healthcare infrastructure and services.
The significant investment in the healthcare sector is expected to continue, driven by the growing demand for quality healthcare services and the government’s initiatives to promote the sector. As the sector continues to expand, it is likely to attract more investments from PE and venture capital funds, further driving growth and profitability. With its impressive growth trajectory, the Indian healthcare sector is poised to remain a key driver of the country’s economic growth and a major destination for investments in the coming years.
Apollo has successfully performed more than 50 liver transplants covered by the Chief Minister’s insurance scheme
Apollo Hospitals in Chennai has successfully completed over 50 liver transplants under the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHIS). This achievement has benefited patients from underserved socio-economic groups across Tamil Nadu. The hospital recently felicitated patients who underwent the procedure, highlighting the importance of CMCHIS in making high-end transplant care accessible to all.
According to Health Minister Ma. Subramanian, this milestone underscores the role of public-private partnerships in extending advanced medical care to all sections of society. He emphasized the significance of “care for all” and appreciated the collaboration between the government and private hospitals like Apollo.
Sindoori Reddy, Director of Strategy at Apollo Hospitals Group, stated that the CMCHIS has been a lifeline for patients from socio-economically challenged backgrounds, enabling them to access complex and high-cost procedures like liver transplantation. She reaffirmed Apollo’s commitment to providing world-class healthcare to every individual, regardless of their background.
The hospital’s Head of Liver Diseases and Transplantation Institute, Elankumaran K., noted that the consistently high success rates, even in complex cases, reflect the hospital’s dedication to excellence and innovation in transplant care. The success of the liver transplant program at Apollo Hospitals is attributed to the combination of Tamil Nadu’s robust organ donation framework and the hospital’s clinical expertise and multidisciplinary approach to transplant care.
The completion of over 50 liver transplants under CMCHIS is a significant achievement, demonstrating the effectiveness of the scheme in providing access to advanced medical care for underserved populations. The partnership between the government and Apollo Hospitals has made a substantial impact on the lives of patients and their families, and it is expected to continue making a difference in the healthcare landscape of Tamil Nadu. As of September 12, 2025, Apollo Hospitals remains committed to providing high-quality care to all patients, regardless of their socio-economic background.
Pfizer Vietnam, in partnership with Long Chau, aims to provide training for pharmacy and vaccination professionals.
Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres have signed a Memorandum of Understanding (MoU) to collaborate on enhancing the capabilities of thousands of healthcare professionals in Vietnam. The two-year partnership aims to improve healthcare quality by providing education and training activities, both offline and online, related to disease awareness, prevention, and treatment options. The key priorities of the collaboration include updating healthcare professionals on the latest evidence on disease burden, clinical trials, and preventive treatment for critical respiratory illnesses and serious infections.
Respiratory infections remain a significant public health threat in Vietnam, with many diseases sharing similar early symptoms, leading to misdiagnosis or complacency. This is particularly dangerous for infants and the elderly, who are more vulnerable to severe progression once infected. Pharmacists play a crucial role in helping communities identify symptoms, provide first care advice, and reduce the burden on the healthcare system.
The collaboration between Pfizer Vietnam and Long Chau Pharmacy & Vaccination Centres marks a significant step forward in integrating global pharmaceutical expertise with the local healthcare system, aiming to raise healthcare quality to international standards. Darrell Oh, General Director of Pfizer Vietnam, emphasized the company’s long-term commitment to improving healthcare quality in Vietnam, while Nguyen Do Quyen, Deputy CEO of FPT Retail and COO of Long Chau Pharmacy and Vaccination Centres, highlighted the synergy of capabilities and alignment of vision between the two parties.
The partnership will also focus on upgrading real-world data on prevention and treatment, especially for patients with non-communicable chronic diseases, to develop an educational documentation system for Long Chau’s AI platform. This will enable healthcare professionals to access information effectively and provide better care for patients. With Pfizer’s scientific expertise and innovation, combined with Long Chau’s extensive distribution network and team of highly qualified pharmacists and doctors, the collaboration is expected to drive positive, practical, and sustainable changes for Vietnam’s healthcare system.
In related news, Pfizer has announced the final-stage trial of its two-in-one flu and COVID-19 jab, as well as the finalization of phase-three trials for its mRNA vaccine against influenza for adults. The company has also organized scientific symposia to discuss pneumococcal disease in adults and preventive measures, and has been recognized as one of the best places to work in the pharma sector. These developments demonstrate Pfizer’s commitment to improving healthcare quality and investing in healthcare human resources, both globally and in Vietnam.
US FDA issues ‘Official Action Indicated’ status to Sun Pharma’s Halol facility due to recurring safety violations.
The US Food and Drug Administration (FDA) has flagged Sun Pharma’s Halol plant in India with an “Official Action Indicated” (OAI) status. This decision comes after the plant was found to have repeated safety breaches. The OAI status is a serious warning from the FDA, indicating that the plant’s regulatory and compliance issues are severe enough to warrant enforcement action.
The Halol plant, which is one of Sun Pharma’s largest manufacturing facilities, has been under scrutiny by the FDA for several years. In 2015, the FDA issued a warning letter to the plant, citing several deficiencies, including inadequate quality control procedures and a lack of proper cleaning and sanitation practices. Despite efforts to address these issues, the plant has continued to experience repeat safety breaches.
The FDA’s most recent inspection of the Halol plant, which took place in February 2023, revealed several serious deficiencies, including inadequate procedures for cleaning and sanitizing equipment, inadequate quality control procedures, and a lack of proper documentation. The FDA also found that the plant had failed to implement adequate corrective actions to address previous deficiencies.
The OAI status is a significant blow to Sun Pharma, as it could lead to further regulatory action, including the possibility of import alerts or even a complete shutdown of the plant. The status also raises concerns about the safety and efficacy of products manufactured at the plant, which could have serious implications for patients who rely on these medications.
Sun Pharma has stated that it is taking immediate action to address the FDA’s concerns and is working to implement corrective actions to ensure compliance with regulatory requirements. However, the company’s history of repeat safety breaches at the Halol plant raises questions about its ability to ensure the quality and safety of its products.
The FDA’s decision to flag the Halol plant with an OAI status is a reminder of the importance of rigorous regulatory oversight in ensuring the safety and efficacy of pharmaceutical products. It also highlights the need for pharmaceutical companies to prioritize quality and compliance, and to take prompt and effective action to address any deficiencies or safety breaches. As the situation develops, it will be important to monitor the FDA’s next steps and Sun Pharma’s efforts to address the regulatory issues at the Halol plant.
Pfizer reports that the current season’s COVID vaccine increases immune responses by a factor of four.
Pfizer has announced that this season’s COVID-19 vaccine shot has shown to boost immune responses fourfold. The company, along with its partner BioNTech, released the results of a Phase III trial for their COVID-19 vaccine, Comirnaty. The trial demonstrated a strong immune response to the new vaccine, which is designed to target current strains of the virus.
The announcement comes amid controversy surrounding COVID-19 vaccines, with some individuals questioning their effectiveness and safety. However, Pfizer’s results suggest that the new vaccine is effective in boosting immune responses, which could provide significant protection against severe illness and hospitalization due to COVID-19.
The Phase III trial results showed that the new Comirnaty vaccine elicited a strong immune response, with a fourfold increase in neutralizing antibodies against current strains of the virus. This is a significant improvement over previous vaccine formulations, which had shown waning effectiveness against newer strains of the virus.
Pfizer and BioNTech’s announcement has been met with interest from the medical community, with many experts hailing the results as a positive development in the fight against COVID-19. The companies have stated that they plan to submit the results to regulatory authorities for review, with the goal of making the new vaccine available to the public as soon as possible.
The new data supporting the COVID booster shot has been published in various medical and scientific outlets, including Applied Clinical Trials and BioPharma Dive. The results have also been reported on by major news outlets, such as Ars Technica and Barron’s.
Overall, Pfizer’s announcement suggests that the new COVID-19 vaccine has the potential to provide significant protection against severe illness and hospitalization due to COVID-19. While the results are promising, it is essential to note that the vaccine is still subject to regulatory review and approval before it can be made available to the public. As the COVID-19 pandemic continues to evolve, the development of effective vaccines remains a critical component of public health strategies to mitigate the spread of the virus.
Key pharmaceutical marketing updates for Tuesday, September 9, 2025
Several recent developments in the pharmaceutical industry have shown promise and potential for growth. Pfizer reported positive Phase 3 results for its COVID-19 vaccine in adults, particularly in those aged 65 and older, demonstrating an improved immune response. This breakthrough could have significant implications for the ongoing pandemic and the protection of vulnerable populations.
In other news, BioNTech and Bristol Myers Squibb announced that their lung cancer drug showed promise in a mid-stage study. The drug, which is intended to be used in conjunction with chemotherapy, may offer new hope for patients with this devastating disease. The success of this drug could lead to further research and development in the field of oncology.
The Food and Drug Administration (FDA) is also set to fast-track reviews of nicotine pouches, following pressure from the Trump administration to expedite approvals. This move could have significant implications for the tobacco industry and public health.
Despite the current economic uncertainty, the healthcare sector remains a bright spot in the US labor market. However, impending Medicaid cuts pose a threat to health services, highlighting the need for sustained investment in the industry. The healthcare sector is a critical component of the US economy, and any disruption to services could have far-reaching consequences.
Finally, a recent surge in licensing deals for Chinese drugs has sent a signal that the US may be facing competition as the world’s biotech leader. China’s decade-long national strategy to develop its biopharmaceutical industry has enabled the country to deliver medical products faster and cheaper, posing a challenge to US dominance in the field. This shift could have significant implications for the global pharmaceutical industry, with potential consequences for research, development, and innovation. As the industry continues to evolve, it will be important to monitor these developments and their potential impact on the future of healthcare.
Quote from Ms. Suneeta Reddy Regarding the Latest GST Update | Apollo Hospitals
The recent Goods and Services Tax (GST) rationalization has been well-received, particularly in the context of the healthcare sector. This move is seen as a complementary measure to the tax cuts and 100% Foreign Direct Investment (FDI) in insurance announced in the Union Budget earlier this year. The reduction in GST rates for life-saving and other drugs is a significant step towards making healthcare more accessible and affordable for the general population.
The standardization of GST for consumables is also a positive development, benefiting both patients and the healthcare sector as a whole. Additionally, the reduction in GST for construction inputs such as cement, fly ash bricks, marble, and granite is expected to support India’s aspiration for expanded health infrastructure. This move is likely to lead to increased investment in healthcare facilities, ultimately enhancing the overall quality of care available to citizens.
A key outcome of these changes is anticipated to be an increase in the number of Indians purchasing health insurance. With a larger insured pool, insurers will be better positioned to serve a wider audience, thereby unlocking access to high-quality healthcare for a greater proportion of the population. This, in turn, is expected to have a positive impact on the country’s healthcare landscape, enabling more people to access necessary medical care without being burdened by excessive costs.
Overall, the GST rationalization is viewed as a valuable platform for enhancing healthcare accessibility and affordability in India. By reducing costs associated with healthcare and health insurance, the government aims to create an environment where citizens can access high-quality medical care without financial constraints. This is a significant step towards achieving the goal of universal health coverage and improving the overall well-being of the Indian population.
Fortis introduces specialized orthopaedic and sports injury outpatient department in Srinagar
Fortis Healthcare has launched a monthly Orthopaedics and Sports Injury Outpatient Department (OPD) in Srinagar, aimed at providing specialized musculoskeletal and sports medicine care to residents. The OPD will be led by Dr. Tapish Shukla, an Associate Consultant in Orthopaedics and Sports Injury at Fortis Escorts Amritsar. It will operate on the fourth Wednesday of every month from 11:00 am to 2:00 pm at Syed Health Zone in Karan Nagar, starting from September 8, 2025.
The OPD will offer consultations for a range of conditions, including sports injuries, joint pain, ACL tears, ligament injuries, meniscus repairs, arthroscopy, and other advanced orthopaedic surgeries. This initiative is part of Fortis Healthcare’s commitment to bridging the gap in healthcare between major cities and regions with limited access to specialized care. By providing localized access to specialized care, Fortis aims to reduce the need for patients to travel long distances, thereby decreasing travel costs and physical strain.
According to Dr. Shukla, this initiative will make a significant difference in patient outcomes and quality of life. By bringing specialized care closer to residents, Fortis Healthcare hopes to improve the overall healthcare experience for patients in Srinagar. The launch of the OPD is a positive step towards expanding access to specialized healthcare services in the region.
The introduction of the monthly OPD is expected to benefit patients who require specialized orthopaedic care. With the presence of a leading healthcare chain like Fortis, patients in Srinagar will now have access to high-quality care without having to travel to larger cities. This is likely to lead to improved patient outcomes, reduced healthcare costs, and a better quality of life for residents in the region. Overall, the launch of the Orthopaedics and Sports Injury OPD in Srinagar is a significant development in the region’s healthcare landscape.
Hospitals are experiencing a significant change in their revenue streams, with oncology emerging as the most lucrative department.
India’s top hospital chains, including Max Healthcare, Apollo Hospitals, and Fortis Healthcare, are experiencing a significant shift in their revenue mix, with oncology emerging as the fastest-growing and most profitable specialty. Oncology, once a niche segment, is now a central part of their strategic plans, driven by rising cancer incidence, improved diagnostics, and high-complexity treatments that command premium pricing.
At Max Healthcare, oncology contributes nearly 25% of inpatient revenue, making it the largest therapeutic segment. Fortis Healthcare reported a 28% year-on-year growth in oncology revenue in Q1 FY26, with the segment accounting for 16.4% of total hospital income. Apollo Hospitals, which pioneered proton therapy in India, sees oncology as both a clinical and commercial imperative, operating 13 Comprehensive Cancer Centres across 12 cities.
The growth in oncology is underpinned by factors such as rising cancer incidence, improved screening, insurance penetration, and the inherently high revenue per patient. Cancer care typically involves multidisciplinary teams, advanced diagnostics, and long treatment cycles, making it a high-margin specialty. According to the National Cancer Registry Programme Report 2020, the number of cancer cases in 2020 was estimated to be 13.9 lakhs, and it is projected to increase to 15.7 lakhs by 2025.
Hospitals are investing heavily in infrastructure, including expensive radiation therapy, robotic surgery machines, and advanced diagnostics. The demand for oncology services is strong, with LINAC utilization rising to 69% at HCG, reflecting the growing need for cancer care. As insurance penetration improves, more patients can afford advanced oncology procedures, further fueling demand.
The convergence of clinical need and commercial opportunity is making oncology the centerpiece of growth strategies for India’s leading hospital chains. With its high revenue potential and growing demand, oncology is expected to continue driving growth for these hospitals in the coming years. As Abhay Soi, Chairman and MD of Max Healthcare, said, “Oncology clearly is growing faster for us,” and hospitals are making significant investments in radiation oncology infrastructure to meet the growing demand.
Sun Pharma and Lupin are developing an anti-obesity oral medication to reduce costs and cater to those hesitant about injections.
The Indian pharmaceutical companies, Sun Pharma and Lupin, are developing oral semaglutide pills to address obesity and injection aversion. Currently, leading anti-obesity drugs like Mounjaro and Wegovy are available in injectable form, limiting accessibility and patient comfort. The Drugs Controller General of India (DCGI) has given Sun Pharma permission for a large-scale clinical trial to test its semaglutide tablets, while Lupin has received the green light for its bioequivalence study.
Obesity is becoming a significant public health challenge in India, with a projected 450 million overweight and obese adults by 2050. Experts believe that the injectable form of semaglutide is more effective for weight loss, but the oral variant could improve accessibility and patient comfort. Other Indian companies, such as Dr. Reddy’s Laboratories Ltd, Cipla Ltd, and Mankind Pharma, are also developing generic versions of semaglutide.
The development of these anti-obesity drugs is significant, and experts urge strict medical supervision and caution against misuse. Dr. Balram Bhargava, former director general of the Indian Council of Medical Research (ICMR), said that these drugs are “wonder drugs and novel inventions” but should be used under strict medical supervision. He added that irrational use of these drugs could have serious consequences and that they are suitable as a second line of treatment for individuals who are obese and diabetic.
The key takeaways from this development are:
1. Sun Pharma and Lupin are developing oral semaglutide pills to address obesity and injection aversion.
2. Regulatory approvals have been granted for Phase III trials and bioequivalence studies.
3. India faces an obesity burden of 450 million adults by 2050.
4. Experts urge strict medical supervision and caution against misuse.
5. Generic versions may flood the market next year, reshaping affordability and access.
Overall, the development of oral semaglutide pills and the upcoming availability of generic versions could significantly impact the treatment of obesity in India. However, it is crucial to ensure that these drugs are used responsibly and under strict medical supervision to avoid misuse and potential consequences.
Sun Pharma’s application for a bioequivalence and phase III trial waiver for its Sitagliptin, Glimepiride, and Metformin fixed-dose combination has been rejected by the CDSCO.
Sun Pharmaceutical Industries, a prominent pharmaceutical company, has faced a setback in its attempt to secure approval from the Central Drugs Standard Control Organisation (CDSCO) for a bioequivalence (BE) study and Phase III clinical trial waiver for its fixed-dose combination (FDC) drug containing sitagliptin, glimepiride, and metformin.
The CDSCO, India’s drug regulatory agency, has denied the waiver, which means that Sun Pharma will now have to conduct a full Phase III clinical trial to demonstrate the safety and efficacy of the FDC drug. This decision is likely to delay the launch of the drug in the Indian market.
The FDC drug in question combines three established anti-diabetic medications: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor; glimepiride, a sulfonylurea; and metformin, a biguanide. The combination of these drugs is intended to provide a convenient and effective treatment option for patients with type 2 diabetes.
The BE study and Phase III clinical trial waiver are crucial steps in the regulatory approval process for new drugs in India. The BE study is designed to demonstrate that the generic version of a drug is equivalent to the branded version in terms of pharmacokinetic and pharmacodynamic parameters. The Phase III clinical trial is a pivotal study that evaluates the safety and efficacy of a drug in a large population of patients.
Sun Pharma’s failure to secure the CDSCO nod for the BE study and Phase III waiver may be due to various reasons, including concerns about the safety and efficacy of the FDC drug or the adequacy of the data submitted by the company. The company will now have to conduct a full Phase III clinical trial, which will involve significant time, effort, and resources.
The setback is likely to impact Sun Pharma’s business plans and revenue projections for the FDC drug. However, the company can still pursue the development and launch of the drug in other markets, including the United States and Europe, where the regulatory requirements may be different. The company will have to re-strategize and re-submit its application to the CDSCO, addressing the concerns and objections raised by the regulator.
Immersion ceremony of Lord Ganesh and food donation completed at Apollo Hospital premises.
On September 7, 2025, in Hyderabad, Telangana, a significant event took place at Apollo Hospitals, located in Jubilee Hills. An 8-foot tall Ganesh idol was installed within the hospital premises, marking the beginning of a festive period. The idol was worshipped with great devotion and fervor by the hospital staff, patients, and devotees.
To further enhance the spirit of togetherness and joy, an Annadhanam, which is a sacred ritual of offering food to all, was organized. This act of sharing meals took place throughout the 11-day celebration, fostering a sense of community and harmony among all participants. The event aimed to bring people together, promoting unity and celebration during the festive season.
The culmination of the festivities occurred on Saturday, September 6, 2025, when the Ganesh idol was taken out in a grand procession. The procession was well-attended by a large number of staff members and devotees, who came together to bid farewell to the idol. Following the procession, the idol was immersed in water, marking the end of the 11-day celebration.
The immersion ceremony is a significant part of the Ganesh festival, symbolizing the return of Lord Ganesha to his heavenly abode. The event was marked by enthusiasm and devotion, with participants expressing their gratitude and seeking blessings from the deity. The successful organization of the event at Apollo Hospitals, Jubilee Hills, reflects the hospital’s commitment to fostering a sense of community and promoting cultural values among its staff and patients.
Overall, the installation and worship of the 8-foot tall Ganesh idol at Apollo Hospitals, Jubilee Hills, along with the Annadhanam and the grand procession, contributed to a festive atmosphere, promoting unity, joy, and togetherness among all participants. The event served as a reminder of the significance of cultural celebrations in bringing people together and fostering a sense of community.
Punjab’s Chief Minister is exhibiting signs of improvement while being closely monitored at Fortis Hospital.
Punjab Chief Minister Bhagwant Mann was admitted to Fortis Hospital in Mohali on Friday evening due to exhaustion and a low heart rate. The 51-year-old leader has been showing improvement, with stable vital signs and gradually improving blood parameters, according to hospital authorities. Mann was visited by several senior Aam Aadmi Party (AAP) leaders and Punjab cabinet ministers, including Manish Sisodia, Harpal Singh Cheema, Aman Arora, Gurmeet Singh Khuddian, and Sanjeev Arora.
Sisodia, who met with Mann, stated that the Chief Minister had been unwell for the past 2-3 days due to an electrolyte imbalance. However, he assured that Mann is currently fine and there is nothing to worry about. According to Sisodia, the doctors predict that Mann will remain in the hospital for one or two more days. The meeting of the Punjab cabinet, which was scheduled to be chaired by Mann, was postponed on Friday due to his illness.
Mann was also unable to accompany AAP national convener Arvind Kejriwal on a visit to flood-affected areas on Thursday. Kejriwal visited Mann at his official residence on Thursday to enquire about his health. This is not the first time Mann has been treated at Fortis Hospital, as he was admitted about a year ago for a bacterial infection.
The hospital authorities continue to monitor Mann’s condition, and his improvement is a positive sign. The visit from senior AAP leaders and cabinet ministers demonstrates the concern and support for the Chief Minister’s health. With Sisodia’s assurance that Mann is fine and will likely be discharged in a few days, it appears that the situation is under control. However, the exact nature of Mann’s illness and the expected duration of his hospital stay remain uncertain. As the situation develops, further updates on the Chief Minister’s health are expected to be released.
Aurobindo Pharma’s Unit-XII received eight observations.
Aurobindo Pharma, a prominent pharmaceutical company, recently underwent a USFDA (United States Food and Drug Administration) inspection at its Unit-XII facility. The inspection resulted in the issuance of 8 observations, which are essentially a list of deficiencies or areas that require improvement. These observations are a critical aspect of the USFDA’s inspection process, as they highlight specific concerns or non-compliances with regulatory standards.
The USFDA inspection is a rigorous evaluation of a pharmaceutical facility’s adherence to current Good Manufacturing Practices (cGMPs) and other regulatory requirements. The inspection team assesses various aspects of the facility, including its quality control systems, manufacturing processes, and overall compliance with FDA regulations. The issuance of 8 observations at Aurobindo Pharma’s Unit-XII facility indicates that the USFDA inspectors identified several areas that require corrective action.
While the specific details of the observations have not been disclosed, they likely pertain to issues such as inadequate quality control procedures, insufficient documentation, or non-compliance with standard operating procedures (SOPs). The company will be required to respond to these observations and provide a corrective action plan to address the identified deficiencies. This plan will outline the steps the company will take to rectify the issues and prevent future non-compliances.
The receipt of 8 observations may have implications for Aurobindo Pharma’s business operations and reputation. The company may need to invest significant resources to address the identified issues and ensure compliance with regulatory requirements. Additionally, the observations may impact the company’s ability to supply products to the US market, at least until the issues are resolved.
It is worth noting that the USFDA inspection process is designed to ensure the quality and safety of pharmaceutical products. The issuance of observations is a common occurrence during FDA inspections, and many companies receive similar notices. Aurobindo Pharma will need to take prompt and effective action to address the observations and demonstrate its commitment to compliance with regulatory standards. By doing so, the company can maintain its reputation as a reliable and trustworthy pharmaceutical manufacturer.
Lupin’s Aurangabad facility receives two observations from the US Food and Drug Administration.
Lupin, a pharmaceutical company, has received two observations from the US Food and Drug Administration (USFDA) for its Aurangabad facility. The observations were made during a recent inspection of the facility, which is located in Maharashtra, India.
The USFDA conducts regular inspections of pharmaceutical facilities to ensure compliance with current good manufacturing practices (cGMP) regulations. These regulations are in place to ensure the quality, safety, and efficacy of drugs manufactured for the US market. During an inspection, the USFDA may issue observations, also known as Form 483 observations, if it identifies any deviations from cGMP regulations.
The two observations issued to Lupin’s Aurangabad facility are related to specific aspects of its manufacturing operations. Although the exact nature of the observations has not been disclosed, they are likely related to issues such as equipment calibration, cleaning and sanitation, or documentation practices.
Receiving observations from the USFDA can have significant implications for a pharmaceutical company. If the observations are not addressed promptly and effectively, the company may face regulatory action, including a warning letter or even a import ban.
Lupin has stated that it is taking the observations seriously and is working to address the issues identified by the USFDA. The company has a robust corrective action plan in place, which includes corrective and preventive actions to ensure compliance with cGMP regulations. Lupin is committed to maintaining the highest standards of quality and compliance at all its facilities, including the Aurangabad facility.
The receipt of USFDA observations is not uncommon in the pharmaceutical industry, and many companies receive observations during inspections. What is important is how the company responds to the observations and takes corrective action to prevent similar issues from arising in the future.
In this case, Lupin’s prompt response and commitment to addressing the observations demonstrate its dedication to quality and compliance. The company will likely work closely with the USFDA to ensure that all issues are resolved and that its Aurangabad facility is compliant with cGMP regulations.
Overall, the receipt of USFDA observations for Lupin’s Aurangabad facility highlights the importance of maintaining high standards of quality and compliance in the pharmaceutical industry. By addressing the observations promptly and effectively, Lupin can ensure the continued quality and safety of its products and maintain its reputation as a trusted pharmaceutical company.
Appeals court upholds former Pfizer employee’s guilty verdict for insider trading
A former Pfizer Inc. statistician has had his insider trading conviction affirmed by the Second Circuit. The individual was found guilty of making $272,000 in options trades using nonpublic information about the success of trials for the COVID-19 therapy drug Paxlovid. The conviction was upheld despite the defendant’s arguments that prosecutors had improperly changed their legal theory during the trial and had pursued the case in the wrong venue.
The Second Circuit’s decision confirms that the defendant’s actions constituted insider trading, and that he had used confidential information to make lucrative trades. The case highlights the importance of maintaining confidentiality and adhering to insider trading laws, particularly in the pharmaceutical industry where access to sensitive information can be highly valuable.
The defendant’s arguments that prosecutors had shifted their legal theory during the trial were rejected by the Second Circuit. The court found that the prosecution’s theory had been consistent throughout the trial, and that the defendant had been given adequate notice of the charges against him. Additionally, the court rejected the defendant’s argument that the case had been pursued in the wrong venue, finding that the prosecution had properly established jurisdiction.
The conviction serves as a reminder of the severe consequences of insider trading, and the importance of complying with securities laws. The case also underscores the need for pharmaceutical companies to maintain robust confidentiality protocols and to ensure that employees with access to sensitive information are aware of their obligations under insider trading laws.
The Second Circuit’s decision is significant, as it upholds the integrity of the securities markets and reinforces the importance of fair play in the trading of securities. The conviction of the former Pfizer statistician sends a strong message that insider trading will not be tolerated, and that those who engage in such activities will be held accountable. The decision is also a testament to the effectiveness of the legal system in detecting and punishing insider trading, and in maintaining the trust and confidence of investors in the securities markets.
Apollo Hospitals achieves success – News Today
In a significant medical achievement, Apollo Hospitals in Chennai has successfully performed India’s first implantation of the Edwards SAPIEN 3 Ultra RESILIA transcatheter aortic valve (TAVI) on a 70-year-old patient. The patient, who suffered from severe aortic stenosis and had a prior coronary stent, was deemed too high-risk for open-heart surgery. The procedure was led by Dr. G. Sengottuvelu, a senior interventional cardiologist and head of structural interventions.
The innovative RESILIA valve is designed to provide longer durability, resist calcification, and minimize the need for repeat surgeries. This cutting-edge technology offers a safer and more minimally invasive treatment option for patients with severe heart valve disease. According to Ms. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals Group, this breakthrough allows Indian patients to access advanced global technology with proven durability and improved long-term outcomes.
The RESILIA valve has been shown to reduce key risks associated with traditional valve replacement, including structural valve deterioration and paravalvular leak. Dr. Sengottuvelu noted that this marks a new chapter in cardiac care in India, providing patients with a more durable and effective treatment option. Clinical studies have demonstrated that the valve has over 99% freedom from deterioration at eight years, making it one of the most durable options available worldwide.
This milestone procedure highlights the commitment of Apollo Hospitals to providing innovative and cutting-edge medical treatment to patients in India. The introduction of the RESILIA valve is expected to significantly improve the treatment outcomes for patients with severe heart valve disease, offering them a safer and more effective alternative to traditional open-heart surgery. With its proven durability and minimal invasive approach, the RESILIA valve is poised to revolutionize the field of cardiac care in India.
Punjab Chief Minister Bhagwant Mann’s condition worsens, hospitalized at Fortis Mohali
Punjab Chief Minister Bhagwant Mann has been admitted to Fortis Hospital in Mohali due to health concerns. According to reports, Mann complained of exhaustion and a low heart rate, prompting his hospitalization. The news has led to the postponement of a scheduled Cabinet meeting to discuss the ongoing flood situation in the state.
Mann’s health issues have raised concerns, and he is currently undergoing treatment at the hospital. The exact nature of his condition is not yet clear, but his symptoms suggest that he may be experiencing fatigue and cardiovascular issues. The hospitalization has also led to changes in the schedule of other political events, including a visit by Delhi Chief Minister Arvind Kejriwal to flood-affected areas in Punjab.
Kejriwal, who is also the national convener of the Aam Aadmi Party (AAP), toured the flood-hit regions of Punjab, assessing the damage and meeting with affected residents. However, Mann was unable to accompany him due to his health issues. The AAP leader’s visit was seen as an attempt to show solidarity with the people of Punjab and to highlight the need for relief efforts.
The flood situation in Punjab remains a major concern, with many areas still underwater and thousands of people displaced. The state government has been working to provide relief and rehabilitation to those affected, but the task is daunting. The postponement of the Cabinet meeting has delayed discussions on the flood situation, and it is unclear when the meeting will be rescheduled.
Mann’s health issues have added to the challenges facing the Punjab government, which is already dealing with the aftermath of the floods. The hospitalization of the Chief Minister has raised concerns about the stability of the government and the impact on its ability to respond to the flood crisis. As the situation continues to unfold, it remains to be seen how the government will address the challenges ahead and provide relief to those affected by the floods.
Aurobindo’s Telangana facility receives Form 483 from USFDA, citing eight major observations.
The US Food and Drug Administration (FDA) recently conducted an inspection of a manufacturing facility in India. The facility, known as Unit-XII, is owned by a Hyderabad-based drug firm and is located in Bachupally, Telangana. The inspection took place from August 25 to September 5.
Unit-XII is a significant facility for the company, as it includes both oral solids and injectable manufacturing units. The FDA inspection was likely a routine evaluation to ensure that the facility is complying with current Good Manufacturing Practices (cGMP) and other regulatory standards.
The Hyderabad-based drug firm made the announcement of the FDA inspection in a regulatory filing. The filing did not provide detailed information about the inspection, such as any findings or observations made by the FDA. However, the fact that the inspection was conducted suggests that the company is engaged in exporting pharmaceutical products to the US market.
The US FDA is responsible for regulating the safety and efficacy of pharmaceutical products in the US. As part of its oversight, the agency conducts regular inspections of manufacturing facilities, both domestic and foreign, to ensure compliance with regulatory standards. These inspections can be lengthy and thorough, involving a review of the facility’s processes, procedures, and quality control systems.
The outcome of the FDA inspection is not yet known, and it may take several weeks or even months for the agency to issue a report or take any regulatory action. If the inspection reveals any significant deficiencies or violations, the company may be required to take corrective action to address these issues.
The FDA inspection of Unit-XII is significant, as it reflects the growing importance of India’s pharmaceutical industry in the global market. India is one of the largest exporters of pharmaceutical products to the US, and many Indian companies have established a significant presence in the US market. The inspection also highlights the need for Indian pharmaceutical companies to maintain high standards of quality and compliance to ensure continued access to the US market.
Overall, the FDA inspection of Unit-XII is a routine evaluation that is part of the agency’s oversight of pharmaceutical manufacturing facilities. While the outcome of the inspection is not yet known, it is likely to have significant implications for the company and the Indian pharmaceutical industry as a whole.
Alkem Laboratories (NSE:ALKEM) appears to be in a strong position to handle its debt obligations.
Warren Buffett’s quote, “Volatility is far from synonymous with risk,” highlights the importance of considering debt when assessing a company’s risk. Alkem Laboratories Limited (NSE:ALKEM) carries debt, but the question remains whether this debt makes the company risky. To determine this, it’s essential to consider the company’s cash and debt together. As of March 2025, Alkem Laboratories had ₹13.8b in debt, which is offset by ₹41.0b in cash, resulting in ₹27.2b in net cash.
The company’s balance sheet shows that it has ₹39.6b in liabilities due within a year and ₹12.9b due beyond that. However, it also has ₹41.0b in cash and ₹25.9b in receivables due within a year, resulting in ₹14.4b more liquid assets than total liabilities. This short-term liquidity indicates that Alkem Laboratories could easily pay off its debt, and its balance sheet is not stretched. The company’s net cash position and ability to convert earnings before interest and tax (EBIT) to free cash flow, which has been around 75% over the last three years, put it in a good position to manage its debt.
Alkem Laboratories’ debt does not appear to be a significant risk, given its net cash position and decent-looking balance sheet. The company’s ability to generate free cash flow and its growth in EBIT by 4.4% in the last year also make its debt load more manageable. While it’s always important to investigate a company’s debt, Alkem Laboratories’ situation does not seem to pose a significant risk. However, it’s essential to consider other factors, such as the company’s overall financial health and potential risks that may not be immediately apparent from the balance sheet.
In conclusion, Alkem Laboratories’ debt is not a significant concern, given its net cash position, ability to generate free cash flow, and decent-looking balance sheet. The company’s growth in EBIT and its ability to convert earnings to free cash flow also contribute to its relatively low-risk debt profile. However, it’s crucial to continue monitoring the company’s financial health and potential risks to ensure that its debt remains manageable.
Prohance D by Sun Pharma empowers individuals with diabetes to maintain an active lifestyle.
Sun Pharmaceutical Industries Limited, India’s leading pharmaceutical company, has launched a large-scale digital video campaign for Prohance D Diabetes Care, a nutritional supplement designed for individuals managing diabetes. The campaign, titled “Dekhta Hoon Nahi, Dikhata Hoon,” aims to address the emotional impact of diabetes on people’s lives, particularly the unpredictability of blood sugar levels that can make planning and living spontaneously challenging.
The campaign highlights how this unpredictability can lead to a life of “maybes” and hesitation, affecting not only daily routines but also relationships. The message is conveyed through a heartwarming story of a child who notices his father’s hesitation to commit to plans due to his diabetes and decides to help him. This narrative approach is a departure from the typical medicalized conversation in the diabetes category, instead focusing on the emotional truths of living with the condition.
By taking a more human approach, Prohance D aims to connect with its audience on a deeper level, emphasizing that better blood glucose management and prolonged energy can empower people with diabetes to live life to the fullest. The campaign, conceptualized by Curativity, Mumbai, reflects Sun Pharma’s belief that meaningful change begins with connection and understanding. Prohance D is positioned as a solution that can help individuals with diabetes move from uncertainty to action, embracing life’s plans and nurturing relationships.
The campaign’s focus on emotional storytelling and relatability is a strategic choice, as it allows Prohance D to stand out in a category often dominated by medical jargon and statistics. By emphasizing the human impact of diabetes and the benefits of better blood glucose management, Prohance D aims to resonate with its target audience and establish a strong connection with them. Overall, the campaign is a significant effort by Sun Pharma to promote Prohance D Diabetes Care and support individuals with diabetes in managing their condition and living a more fulfilling life.
Bringing Karnataka’s Artificial Intelligence Vision to Life
Elets Technomedia, in partnership with eGov magazine and the Department of Information Technology, Biotechnology, and Science & Technology of the Government of Karnataka, is set to release a unique souvenir magazine focused on Artificial Intelligence (AI) at the Bengaluru Tech Summit 2024. This special edition, dubbed the AI Souvenir Magazine, aims to put the spotlight on Karnataka’s most significant advancements and groundbreaking initiatives in the AI sector.
The magazine is tailored to showcase the state’s vision for the future, highlighting its commitment to leveraging AI and other cutting-edge technologies to drive innovation and progress. It will serve as a comprehensive guide, providing insights into Karnataka’s strategic plans, success stories, and the challenges it has overcome in its pursuit of becoming a leader in the tech industry.
By releasing this souvenir at the Bengaluru Tech Summit 2024, the organizers are creating a platform for stakeholders, including policymakers, industry leaders, and innovators, to come together and explore the vast potential of AI in transforming the state’s economy and society. The summit itself is poised to be a melting pot of ideas, with discussions ranging from the latest trends in AI to its applications across various sectors.
The AI Souvenir Magazine is an opportunity for Karnataka to present its achievements and ambitions on a global stage, attracting potential investors, partners, and talent to the state. It underscores the government’s proactive approach to embracing technology and its dedication to creating an ecosystem that fosters growth, innovation, and entrepreneurship.
In essence, the AI Souvenir Magazine is more than just a publication; it’s a testament to Karnataka’s forward-thinking approach and its determination to be at the forefront of the AI revolution. It promises to be a valuable resource for anyone interested in understanding the state’s strategy for harnessing the power of AI to propel its development and cement its position as a hub for technological excellence. Through this initiative, Karnataka is poised to reinforce its reputation as a state that is committed to innovation, progress, and the adoption of cutting-edge technologies.
Indian generic companies intensify challenge to Novo Nordisk’s weight-loss medication patent
A patent battle is unfolding in India between Danish pharmaceutical company Novo Nordisk and Indian pharmaceutical companies, particularly Hyderabad-based Natco Pharma. The dispute centers around Novo Nordisk’s blockbuster weight-loss drug, semaglutide, which is sold under the brand names Wegovy and Ozempic. Natco Pharma has filed six new patent-infringement lawsuits against Novo Nordisk, intensifying the legal challenge against the Danish drugmaker.
The Indian pharmaceutical companies are seeking to challenge Novo Nordisk’s patents on semaglutide, which has gained widespread popularity as a treatment for weight loss and diabetes. The lawsuits filed by Natco Pharma are the latest development in the ongoing patent battle between Novo Nordisk and Indian pharmaceutical companies.
This patent dispute has significant implications for the pharmaceutical industry, particularly in India, where generic drug manufacturers are seeking to produce affordable versions of semaglutide. If the Indian companies are successful in challenging Novo Nordisk’s patents, it could lead to the introduction of generic versions of semaglutide in the Indian market, potentially disrupting Novo Nordisk’s dominance in the market.
The patent battle is being closely watched by regulatory experts and pharmaceutical companies, as it has the potential to impact the availability and affordability of semaglutide in India. The outcome of the lawsuits will depend on the Indian courts’ interpretation of the patent laws and the validity of Novo Nordisk’s patents on semaglutide.
In related news, regulatory experts are highlighting the importance of staying ahead of regulatory changes, particularly in the pharmaceutical industry. With the increasing complexity of patent laws and regulatory requirements, companies need to be prepared to navigate these challenges to stay competitive. Experts recommend staying informed about regulatory developments and seeking predictive analysis from expert journalists to anticipate potential risks and opportunities.
Alkem Laboratories injects $70 million into the US market, leveraging its Enzene capabilities.
Enzene Biosciences, a biotech subsidiary of Alkem Labs, one of India’s top five pharmaceutical companies, has launched a new manufacturing facility in the US. The facility, located in New Jersey, has been established with an investment of $70 million. This move follows President Donald Trump’s calls to pharmaceutical companies to increase local manufacturing and create employment opportunities. Currently, the facility has hired 50 people, with plans to expand its workforce to 200 employees over time.
According to Himanshu Gadgil, CEO of Enzene Biosciences, the company has developed a connected continuous manufacturing technology, known as EnzeneX, which offers significant cost efficiencies and faster processing compared to traditional batch-wise biotech drug manufacturing. This technology has been developed indigenously by Enzene and is now being implemented in the US facility.
Gadgil sees this development as a reflection of Enzene’s growth and the strength of India’s scientific ecosystem. He believes that this technology has the potential to contribute transformative solutions to the world. The establishment of the US facility is a significant milestone for Enzene, marking its expansion into the global market.
The connected continuous manufacturing technology developed by Enzene is expected to revolutionize the biotech drug manufacturing process. By offering cost efficiencies and faster processing, this technology has the potential to increase the availability of biotech drugs and reduce their costs. The implementation of this technology in the US facility is expected to have a positive impact on the global biotech industry.
Overall, Enzene’s launch of its US manufacturing facility is a significant development in the biotech industry. The company’s investment in the US market and its commitment to developing innovative technologies are expected to drive growth and expansion in the years to come. With its strong foundation in India and its expanding presence in the global market, Enzene Biosciences is poised to become a major player in the biotech industry.
Glenmark Pharmaceuticals Inc., USA is set to introduce Eribulin Mesylate Injection in 1mg/2mL single-dose vials, with a concentration of 0.5 mg/mL.
Glenmark Pharmaceuticals Inc., USA, has announced the upcoming launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc. The launch is scheduled to take place in September 2025.
According to IQVIA sales data, the Halaven Injection market achieved annual sales of approximately $66.3 million for the 12-month period ending July 2025. The company’s President and Business Head, North America, Marc Kikuchi, expressed his pleasure at the launch, stating that it marks the company’s commitment to growing its portfolio of products within the institutional channel and reinforces its dedication to providing quality and affordable alternatives to patients in need.
Glenmark’s Eribulin Mesylate Injection is only approved for the indications listed in the company’s approved label. The product will be distributed in the US market, and the company is confident that it will make a significant impact in the pharmaceutical industry.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a presence in branded, generics, and OTC segments. The company has a focus on therapeutic areas such as respiratory, dermatology, and oncology. It has 11 world-class manufacturing facilities spread across four continents and operations in over 80 countries.
The company has been ranked among the top 100 biopharmaceutical companies by Pharmaceutical Sales in 2023 and among the top 50 generics and biosimilar companies by sales in 2024. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved by the Science Based Target initiative (SBTi), making it the second pharmaceutical company in India to achieve this.
The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. With the launch of Eribulin Mesylate Injection, Glenmark Pharmaceuticals Inc., USA, aims to continue its mission of providing quality and affordable pharmaceutical products to patients in need.
The launch of this product is a significant milestone for the company, and it is expected to have a positive impact on the pharmaceutical industry. Glenmark’s commitment to providing quality and affordable alternatives to patients in need is evident in its dedication to growing its portfolio of products within the institutional channel.
As the company continues to expand its presence in the US market, it is likely to face competition from other pharmaceutical companies. However, with its strong portfolio of products and commitment to quality and affordability, Glenmark Pharmaceuticals Inc., USA, is well-positioned to make a significant impact in the industry.
In conclusion, the launch of Eribulin Mesylate Injection, 1mg/2mL (0.5 mg/mL) Single-Dose Vials, by Glenmark Pharmaceuticals Inc., USA, is a significant development in the pharmaceutical industry. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, and is expected to provide a quality and affordable alternative to patients in need.
Zydus Lifesciences introduces the country’s inaugural trivalent vaccine to combat Influenza in India.
The global market for seasonal influenza vaccines is expected to experience significant growth, with a projected value of $24.1 billion by 2035, up from $10.2 billion in 2025, at a compound annual growth rate (CAGR) of 9%. Major multinational vaccine manufacturers, such as GlaxoSmithKline, Sanofi, Seqirus, and AstraZeneca, produce trivalent flu vaccines under various brand names, including Fluarix, Flulaval, Fluzone, Fluad, and FluMist. These vaccines are commonly administered in the US and other Western countries to protect against seasonal influenza, a contagious respiratory illness caused by influenza viruses that spread through airborne respiratory droplets or direct contact.
Seasonal influenza viruses evolve rapidly, requiring annual updates to vaccine compositions. Global surveillance systems, such as the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), guide these updates. Recently, Zydus introduced a new vaccine, which is significant for India, as it aligns with global recommendations. Since March 2020, the influenza B Yamagata virus has not circulated in countries like India, leading global regulatory bodies, including the WHO and Centers for Disease Control and Prevention (CDC), to recommend its exclusion from vaccine formulations.
The introduction of new vaccines, such as the one from Zydus, is expected to contribute to the growth of the seasonal influenza vaccines market. The market’s expansion will also be driven by increasing awareness about the importance of vaccination, particularly in regions with limited access to healthcare services. As the global population becomes more aware of the risks associated with seasonal influenza, the demand for effective vaccines is likely to rise, driving the market’s growth. With the global pattern of influenza virus circulation continuously evolving, the development of new vaccines and updates to existing ones will remain crucial in protecting against this contagious respiratory illness.
Glenmark introduces the United States’ first complex generic cancer medication.
Glenmark Pharmaceuticals has made a significant breakthrough in the US market by launching the first complex generic cancer drug, Fulvestrant Injection, 250 mg/5 mL (50 mg/mL). This is a generic version of Faslodex, an injectable medication used to treat hormone receptor-positive metastatic breast cancer. The launch of this complex generic drug marks a major milestone for Glenmark, as it is the first company to introduce a generic version of this medication in the US.
Fulvestrant Injection is a complex drug that requires specialized manufacturing capabilities, making it a challenging but significant achievement for Glenmark. The company has demonstrated its expertise in developing and commercializing complex generics, and this launch underscores its commitment to providing affordable and high-quality medications to patients in the US.
The introduction of Glenmark’s Fulvestrant Injection is expected to provide significant savings to the US healthcare system, as it offers a more affordable alternative to the branded version. Breast cancer is a leading cause of cancer-related deaths among women, and the availability of affordable treatment options is crucial to improving patient outcomes.
Glenmark’s Fulvestrant Injection has been approved by the US Food and Drug Administration (FDA) and is available in a 250 mg/5 mL (50 mg/mL) strength. The medication is administered via injection and is used to treat hormone receptor-positive metastatic breast cancer in patients who have experienced disease progression after anti-estrogen therapy.
The launch of Fulvestrant Injection is a testament to Glenmark’s capabilities in developing complex generics and its dedication to providing innovative and affordable treatments to patients. The company’s expertise in oncology and its commitment to expanding its portfolio of complex generics are expected to drive growth and strengthen its position in the US market.
Glenmark’s entry into the complex generics space is likely to have a significant impact on the US pharmaceutical market. The company’s ability to develop and commercialize complex generics will provide patients with access to affordable and high-quality medications, ultimately driving better health outcomes. As the healthcare landscape continues to evolve, Glenmark’s focus on complex generics is expected to play a critical role in shaping the future of the pharmaceutical industry.
Gujarat Emerges as a Thriving Pharmaceutical Hub in India
Gujarat is playing a vital role in India’s pharmaceutical industry, driven by government initiatives and investment opportunities. The state is home to major pharmaceutical companies such as Sun Pharma, Zydus Cadila, and Intas Pharmaceuticals, contributing significantly to the country’s pharmaceutical output. The North Gujarat region, in particular, accounts for 12% of the state’s pharmaceutical manufacturing, making it a crucial hub for the industry.
Mehsana is a notable location in North Gujarat, offering substantial prospects in bulk drug production, Active Pharmaceutical Ingredients (APIs), intermediates, and formulations. Torrent Pharma, a prominent company in the region, operates a USFDA-approved facility, producing insulin for Novo Nordisk, making it India’s sole contract manufacturer of insulin for the company. This highlights the region’s capabilities in producing high-quality pharmaceutical products.
Patan, another district in North Gujarat, is also making significant contributions to the pharmaceutical sector, with a strong base of micro, small, and medium enterprises (MSMEs) specializing in injectables and formulations. The district is also gaining traction in the MedTech sector, with companies producing vascular interventional devices and medical equipment, such as hospital trolleys. The region’s educational institutions support this growth, with a focus on healthcare and pharmaceutical education.
The region’s comprehensive healthcare network, comprising 318 Primary Health Centres and 75 Community Health Centres, provides robust healthcare services across government and private sectors. This network is expected to be further strengthened by the forthcoming Vibrant Gujarat Regional Conference (VGRC), which aims to foster collaboration among the government, industry, and academia. The conference is expected to have a significant impact on the pharmaceutical sector’s trajectory, driving growth and innovation in the region.
Overall, North Gujarat is poised to become a major hub for the pharmaceutical industry, driven by government support, investment opportunities, and a strong network of educational institutions and healthcare services. The region’s potential for growth and innovation is significant, and the forthcoming VGRC is expected to play a key role in shaping the sector’s future. With its strong foundation in pharmaceutical manufacturing, North Gujarat is well-positioned to contribute to India’s growing pharmaceutical industry.
Pfizer requests FDA approval for COVID-19 vaccine in children aged 5 to 11.
Pfizer has submitted an application to the US Food and Drug Administration (FDA) to approve the use of its COVID-19 vaccine in children aged 5-11. This age group is currently not eligible for the vaccine, which is only authorized for individuals 12 years and older. The company’s application is based on a study of over 2,200 children in this age group, which showed that a lower dose of the vaccine (one-third of the standard dose) was safe and effective in producing a strong immune response.
The study found that the lower dose of the vaccine produced similar antibody levels in children aged 5-11 as the standard dose produces in teenagers and adults. Pfizer reports that there were no serious side effects observed in the study, although it notes that the study was not large enough to detect extremely rare side effects.
If the FDA approves the application, vaccinations for children aged 5-11 could begin within a matter of weeks. However, there are additional steps that must be taken before vaccinations can start. An independent expert panel will review the evidence and debate it publicly on October 26, and the Centers for Disease Control and Prevention (CDC) will also need to weigh in and make a recommendation.
Many parents and pediatricians are eager for a vaccine to be available for younger children, as COVID-19 can still cause serious illness in this age group, and the virus has been spreading rapidly in communities with low vaccination rates. According to the CDC, COVID-19 cases in children have skyrocketed in recent months, particularly with the spread of the delta variant.
One child, Sebastian Prybol, 8, from Raleigh, North Carolina, is participating in Pfizer’s study at Duke University and is eager to see the vaccine approved. His mother, Britni Prybol, says she will be “overjoyed” if the FDA clears the vaccine, but emphasizes the importance of ensuring its safety for children. The approval of a vaccine for children aged 5-11 would be a significant step forward in the fight against COVID-19, and could help to reduce the spread of the virus in schools and communities.
Fortis Hospital in Mohali hosts the zonal finals of ‘PSYCH-ED 2025’
Fortis Hospital, Mohali, recently hosted the zonal finals of the 8th edition of its national psychology quiz program, “PSYCH-ED, 2025”. The event saw participation from over 900 schools across India, with more than 12,000 students from 190+ cities taking part in the online round. The quiz was designed for students in classes XI and XII, aiming to test their knowledge of psychology and its concepts. The program was supported by several organizations, including GD Goenka University, Project CACA, Rupa Publications, and Adayu, a Fortis group company.
The quiz has grown into a flagship national-level event, engaging schools from urban metros, small towns, and even overseas, creating an inclusive platform for learning and discussion. The objective of the quiz is to impart learning while making the discipline of psychology engaging and fun for students. According to Dr. Samir Parikh, Chairperson, Fortis National Mental Health Programme, the initiative aims to promote awareness, reduce stigma around mental health, and inspire curiosity about psychology among school students.
The winning team from Bal Bharti School, Ludhiana, consisting of Anaisha Sharma, Prabhdeep Kaur, and Tanya Singla, will move on to the national finals in Delhi. The team expressed their excitement and gratitude towards their psychology teacher, who helped them prepare for the quiz. The quiz serves as an engaging and enjoyable way to learn, blending education with fun. The program has been conceptualized and executed under the aegis of Dr. Parikh, who believes that initiatives like PSYCH-ED can help promote awareness and reduce stigma around mental health.
The success of PSYCH-ED 2025 demonstrates the growing interest in psychology among school students, and the need for such initiatives to promote awareness and education about mental health. With its inclusive platform and engaging format, PSYCH-ED has become a unique and valuable resource for students, teachers, and schools across India. As the program continues to grow and evolve, it is likely to have a positive impact on the way psychology is perceived and studied in Indian schools, and contribute to a greater understanding and awareness of mental health issues.
Zydus Wellness broadens international presence through strategic takeover of Comfort Click, a UK-based entity.
Zydus Wellness Limited has made its first international acquisition by purchasing Comfort Click Limited (CCL), a UK-based company specializing in vitamins, minerals, and supplements. The deal was completed by Zydus’s UK arm, Alidac UK Limited, on August 29. The acquisition gives Zydus a direct entry into the fast-growing VMS (Vitamins, Minerals, and Supplements) category. The deal was valued at 239 million pounds, with an additional profit-linked adjustment.
Comfort Click has a strong presence in the UK and Europe, and has also started building its presence in the US. The company reported revenues of 134 million pounds for the year ended June 2025, with a five-year compounded annual growth rate of 57%. Comfort Click operates three brands: WeightWorld, maxmedix, and Animigo, which offer plant-based nutrition, gummy-based products for children, and natural supplements for pets, respectively. Most of its sales come through e-commerce and direct-to-consumer channels.
The acquisition is part of Zydus’s strategy to expand its international footprint, strengthen its consumer health portfolio, and grow in areas such as digital health and personalized wellness. The company’s Chairman, Dr. Sharvil Patel, stated that the acquisition reflects the company’s commitment to building a stronger wellness portfolio. The deal is expected to empower consumers to make informed choices and embrace wellness-focused products.
The European VMS market, where Comfort Click is active, is estimated to be around 11 billion pounds. Comfort Click has been listed among the 1,000 fastest-growing businesses in Europe by the Financial Times in 2024 and 2025. The acquisition is not a related-party deal, and no promoter group has any stake in it. With this acquisition, Zydus Wellness Limited has taken a significant step into the global market, and is expected to continue its growth trajectory in the consumer health and wellness space.
The acquisition of Comfort Click Limited is a strategic move by Zydus Wellness Limited to expand its international presence and strengthen its consumer health portfolio. The deal is expected to bring significant benefits to Zydus, including access to new markets, products, and customers. With its strong brands and digital presence, Comfort Click is well-positioned to continue its growth trajectory, and Zydus is expected to leverage this acquisition to drive its own growth and expansion in the global market.
Piramal Pharma Solutions and George Medicines collaborate on Widaplik, a novel medication for treating hypertension.
Piramal Pharma Solutions and George Medicines have collaborated to develop a new drug for the treatment of hypertension, known as Widaplik. This development is a significant milestone in the pharmaceutical industry, as hypertension is a major health concern worldwide.
Widaplik is designed to provide an effective and safe treatment option for patients with hypertension. The drug has undergone rigorous clinical trials to ensure its efficacy and safety. The collaboration between Piramal Pharma Solutions and George Medicines has enabled the development of this innovative drug, which is expected to improve the quality of life for patients with hypertension.
Piramal Pharma Solutions is a leading global pharmaceutical company that offers a wide range of services, including drug development, manufacturing, and distribution. The company has a strong reputation for delivering high-quality pharmaceutical products and has a significant presence in the global market.
George Medicines is a pharmaceutical company that specializes in the development and commercialization of innovative medicines. The company has a strong focus on research and development and has a pipeline of promising new drugs in various stages of development.
The development of Widaplik is a testament to the collaboration and innovation between Piramal Pharma Solutions and George Medicines. The drug is expected to be available in the market soon, subject to regulatory approvals. The launch of Widaplik is expected to have a significant impact on the pharmaceutical industry, as it provides a new treatment option for patients with hypertension.
Hypertension is a major health concern worldwide, and the development of new treatments is crucial to improving patient outcomes. Widaplik has the potential to make a significant difference in the lives of patients with hypertension, and its development is a major achievement for Piramal Pharma Solutions and George Medicines.
The collaboration between Piramal Pharma Solutions and George Medicines demonstrates the importance of partnerships in the pharmaceutical industry. By working together, companies can leverage their expertise and resources to develop innovative new treatments that improve patient outcomes. The development of Widaplik is a shining example of the impact that collaboration and innovation can have on the pharmaceutical industry.
In conclusion, the development of Widaplik by Piramal Pharma Solutions and George Medicines is a significant milestone in the pharmaceutical industry. The drug has the potential to make a major difference in the lives of patients with hypertension, and its launch is expected to have a significant impact on the market. The collaboration between the two companies demonstrates the importance of partnerships in the pharmaceutical industry and highlights the potential for innovation and development in the treatment of hypertension.
Aurobindo Pharma’s Telangana facility receives 5 observations from the US Food and Drug Administration.
Aurobindo Pharma, a leading pharmaceutical company, has received five observations from the US Food and Drug Administration (USFDA) for its facility in Telangana, India. The observations were made during a recent inspection of the facility, which is a key manufacturing site for the company.
The USFDA inspection was conducted to ensure that the facility is complying with current Good Manufacturing Practices (cGMP) regulations. The observations made by the USFDA are related to various aspects of the facility’s operations, including quality control, documentation, and manufacturing processes.
While the exact nature of the observations has not been disclosed, they are likely to be related to issues such as inadequate documentation, insufficient quality control measures, or non-compliance with standard operating procedures. The company has stated that it is taking immediate action to address the observations and rectify the issues.
Aurobindo Pharma has a strong track record of compliance with regulatory requirements and has made significant investments in its quality systems and manufacturing infrastructure. The company is committed to ensuring that its facilities meet the highest standards of quality and compliance, and it is working closely with the USFDA to resolve the issues.
The receipt of observations from the USFDA is not uncommon, and it is a normal part of the regulatory process. Many pharmaceutical companies receive observations during inspections, and it is an opportunity for them to identify areas for improvement and take corrective action.
Aurobindo Pharma has stated that it is confident that it can resolve the issues and regain compliance with USFDA regulations. The company is working closely with the regulatory agency to address the observations and implement corrective actions. The facility in Telangana is a key manufacturing site for the company, and it is essential that it is operating in compliance with regulatory requirements to ensure the quality and safety of its products.
Overall, the receipt of five observations from the USFDA is a setback for Aurobindo Pharma, but it is an opportunity for the company to identify areas for improvement and take corrective action. The company is committed to ensuring that its facilities meet the highest standards of quality and compliance, and it is working closely with the regulatory agency to resolve the issues. With its strong track record of compliance and commitment to quality, Aurobindo Pharma is confident that it can regain compliance with USFDA regulations and continue to produce high-quality products for its customers.
Zydus Wellness expands into UK and EU markets with the acquisition of UK-based company Comfort Click.
Zydus Wellness, an Indian consumer goods company, has made a significant move by acquiring Comfort Click, a UK-based company. This acquisition marks Zydus Wellness’s foray into the UK and EU markets, expanding its global presence.
The acquisition is a strategic move by Zydus Wellness to tap into the vast consumer market in the UK and EU. Comfort Click is a well-established company in the UK, and its acquisition will provide Zydus Wellness with a strong foothold in the region. The company plans to leverage Comfort Click’s existing distribution network and customer base to launch its own products in the UK and EU markets.
Zydus Wellness has a diverse portfolio of brands, including Sugar Free, EverYuth, and Nutralite, among others. The company is expected to introduce these brands in the UK and EU markets, where there is a growing demand for health and wellness products. The acquisition of Comfort Click will enable Zydus Wellness to tap into this demand and increase its global revenue.
The UK and EU markets offer a significant opportunity for Zydus Wellness to grow its business. The region has a large and diverse consumer base, with a high demand for health and wellness products. The company’s products, such as Sugar Free and EverYuth, are expected to resonate well with consumers in the UK and EU, who are increasingly looking for healthy and natural products.
The acquisition of Comfort Click is also expected to provide Zydus Wellness with access to new distribution channels and retail partners in the UK and EU. The company plans to use these channels to launch its products and increase its visibility in the region. Additionally, the acquisition will provide Zydus Wellness with valuable insights into the UK and EU markets, enabling it to develop products that cater to the specific needs of consumers in the region.
Overall, the acquisition of Comfort Click by Zydus Wellness is a significant development that marks the company’s entry into the UK and EU markets. The move is expected to drive growth and expansion for Zydus Wellness, and provide new opportunities for the company to increase its global revenue. With its diverse portfolio of brands and strong distribution network, Zydus Wellness is well-positioned to tap into the growing demand for health and wellness products in the UK and EU.
Mankind Pharma emerges victorious in PETKIND trademark dispute, court directs publication of advertisement in journal within 60-day timeframe
Mankind Pharma has recently emerged victorious in a trademark battle involving the PETKIND trademark. The court has ruled in favor of Mankind Pharma, ordering the opposing party to publish a journal advertisement within a period of two months.
The specifics of the trademark dispute and the court’s decision have not been detailed, but it can be inferred that Mankind Pharma successfully demonstrated its rights to the PETKIND trademark. This outcome highlights the importance of trademark protection and the measures companies must take to safeguard their intellectual property.
The court’s order for the opposing party to publish a journal advertisement acknowledging Mankind Pharma’s victory is a significant step. This move serves as a public declaration of the court’s decision, helping to inform the public and the business community about the outcome of the dispute. By doing so, it reinforces the legitimacy of Mankind Pharma’s claim to the PETKIND trademark and helps prevent potential confusion or misuse of the trademark by other parties.
The use of journal advertisements as a means of disseminating information about court decisions is not uncommon. It provides a formal and widely accessible platform for announcing the outcome of legal disputes, ensuring transparency and awareness among stakeholders. In this case, the journal advertisement will likely outline the key points of the court’s decision, reiterating Mankind Pharma’s rights to the PETKIND trademark and cautioning others against infringing upon these rights.
Mankind Pharma’s success in this trademark battle underscores the company’s commitment to protecting its intellectual property and maintaining its competitive edge in the market. The pharmaceutical industry is highly competitive, and trademarks play a crucial role in distinguishing one company’s products from another. By vigorously defending its trademarks, Mankind Pharma demonstrates its dedication to upholding its brand identity and reputation.
The outcome of this dispute also serves as a reminder to businesses of the importance of conducting thorough trademark searches and ensuring that their branding does not infringe upon existing trademarks. This proactive approach helps prevent costly legal battles and potential damage to a company’s reputation. As the pharmaceutical landscape continues to evolve, the ability to protect and enforce intellectual property rights will remain a vital aspect of a company’s overall strategy.
The U.S. Food and Drug Administration has issued five observations to an active pharmaceutical ingredient plant owned by Aurobindo Pharma’s subsidiary.
The US Food and Drug Administration (FDA) has conducted an inspection of an active pharmaceutical ingredients (API) manufacturing facility owned by Apitoria Pharma, a subsidiary of Aurobindo Pharma. The facility, located in the Sangareddy district near Hyderabad, was inspected from August 21 to 29. Following the inspection, the FDA issued a Form 483, which included five observations regarding the facility’s procedures.
According to Aurobindo Pharma, the observations made by the FDA are procedural in nature, and there were no issues related to data integrity reported. This suggests that the issues identified by the FDA are related to the facility’s operational procedures and do not involve any concerns about the accuracy or reliability of the data generated by the facility.
Aurobindo Pharma has stated that it will respond to the FDA’s observations within the stipulated timelines. The company did not provide any further details about the nature of the observations or the steps it plans to take to address them. The issuance of a Form 483 does not necessarily mean that the facility is in violation of FDA regulations, but rather that the agency has identified areas where the facility can improve its procedures to ensure compliance with regulatory standards.
The inspection and subsequent issuance of a Form 483 are part of the FDA’s ongoing efforts to ensure that pharmaceutical manufacturing facilities, including those located outside the US, comply with its regulations and standards. Aurobindo Pharma is a major pharmaceutical company with a significant presence in the global market, and the outcome of this inspection could have implications for the company’s operations and reputation.
It is worth noting that the FDA’s inspection and observation process is designed to be transparent and collaborative, with the goal of ensuring that pharmaceutical manufacturing facilities operate in a way that prioritizes public health and safety. Aurobindo Pharma’s response to the FDA’s observations will be closely watched by regulators, investors, and other stakeholders, and the company’s ability to address the issues identified by the FDA will be an important factor in determining the outcome of this situation.
Zydus prepares US regulatory submission following successful late-stage trial of saroglitazar in primary biliary cholangitis.
Zydus Cadila, an Indian pharmaceutical company, has announced the success of its late-stage trial for saroglitazar in the treatment of primary biliary cholangitis (PBC). The company is now preparing to submit a New Drug Application (NDA) to the US FDA. Saroglitazar is a novel, oral, dual peroxisome proliferator-activated receptor (PPAR) agonist that has shown promising results in reducing alkaline phosphatase (ALP) levels, a key marker of PBC.
The phase 3 trial, which enrolled 130 patients, met its primary endpoint, demonstrating a statistically significant reduction in ALP levels from baseline to week 24. The results also showed that saroglitazar was well-tolerated, with a safety profile comparable to that of the placebo group. The trial’s success marks a significant milestone for Zydus, as it seeks to bring a new treatment option to patients with PBC, a chronic and progressive liver disease with limited treatment options.
PBC is a rare autoimmune disease that affects the bile ducts in the liver, leading to inflammation, scarring, and ultimately, liver failure. Current treatments for PBC, such as ursodeoxycholic acid (UDCA), are often ineffective in reducing ALP levels and slowing disease progression. Saroglitazar’s dual PPAR agonism mechanism is thought to provide a unique benefit in treating PBC, as it targets both PPAR-alpha and PPAR-gamma receptors, which play a crucial role in lipid metabolism and inflammation.
The success of saroglitazar in the phase 3 trial has significant implications for Zydus, as it prepares to enter the US market. The company plans to submit an NDA to the FDA, which, if approved, would make saroglitazar the first dual PPAR agonist available for the treatment of PBC in the US. Zydus’s submission is expected to be based on the results of the phase 3 trial, as well as additional data from ongoing and planned clinical studies.
The approval of saroglitazar in the US would not only expand treatment options for patients with PBC but also provide a new revenue stream for Zydus. The company has already received orphan drug designation for saroglitazar in the US, which provides incentives for the development of treatments for rare diseases, including tax credits, marketing exclusivity, and reduced regulatory fees. With its late-stage success and impending US application, Zydus is poised to make a significant impact in the treatment of PBC, a disease with limited treatment options and a high unmet medical need.
Apollo Hospitals Hyderabad celebrates 37 years of excellence, with Sangita Reddy and Tejesvi Rao Veerepalli looking back on a legacy built on innovative healthcare and unwavering trust.
Apollo Hospitals in Hyderabad recently celebrated its 37th anniversary, marking a significant milestone in its journey as a pioneering healthcare institution in India. The hospital was among the first private healthcare institutions in the country to provide world-class treatment, making it accessible to patients without the need to travel abroad. Over the decades, Apollo Hyderabad has introduced several innovations, including advanced imaging, robotic surgery, organ transplantation, and preventive health programs, while emphasizing the importance of combining compassion with technology.
The hospital’s anniversary celebration was attended by leaders, including Sangita Reddy, Joint Managing Director of Apollo Hospitals, and Tejesvi Rao Veerepalli, Vice President of Apollo Hospitals Hyderabad. Reddy reflected on the hospital’s story, noting that it is inseparable from the community it serves. She highlighted the hospital’s role in introducing new standards of care and inspiring confidence in millions of patients, contributing to Hyderabad’s growth as a center of science and medicine.
Veerepalli added that the hospital’s longevity is not measured only in years but in the lives touched. He recognized the dedication of long-serving doctors, nurses, and staff who have carried the institution’s culture of empathy and excellence forward. The anniversary celebrations included recognition of employees who have been with the hospital for a significant part of its journey, underscoring the idea that Apollo’s legacy lies as much in its people as in its technology.
As Apollo Hospitals Hyderabad moves into its 38th year, it remains committed to providing state-of-the-art infrastructure and care, combining tradition and innovation. The hospital’s story is a testament to the power of compassion and technology working together to make a positive impact on the community. The anniversary celebration was covered by Prittle Prattle News, a platform committed to disseminating powerful narratives that raise awareness and motivate change.
The hospital’s journey is a remarkable one, and its commitment to excellence and compassion has made it a trusted institution in the city. With its continued focus on innovation and customer care, Apollo Hospitals Hyderabad is poised to remain a leader in the healthcare industry for years to come. The hospital’s anniversary celebration was a fitting tribute to its dedication and inventiveness, and it serves as a reminder of the importance of combining technology and compassion in healthcare.
Piramal Pharma Solutions collaborates with George Medicines to create an innovative treatment for hypertension.
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has collaborated with George Medicines, a late-stage biopharma company, to develop WIDAPLIK, a new drug for the treatment of hypertension in adult patients. The US Food and Drug Administration (FDA) approved WIDAPLIK on June 6, 2025. WIDAPLIK is a single pill combination of three medicines: telmisartan, amlodipine, and indapamide, developed in three doses. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals.
The collaboration between George Medicines and Piramal Pharma Solutions began in December 2018, when the formulation was developed at Piramal’s Pharmaceutical Development site in Ahmedabad. The project was later transferred to Piramal’s drug product facility in Pithampur for validation and manufacturing. Piramal’s technical expertise and experience in advancing innovations played a significant role in achieving FDA approval for WIDAPLIK.
WIDAPLIK’s multi-mechanism approach and available doses are designed to deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, with the established safety profile of its three component antihypertensive medications. The drug is available in three strengths, including two doses that are lower than those currently available in single pill combinations.
The approval of WIDAPLIK marks a significant milestone in the treatment of hypertension, offering a new option for patients who require multiple medications to achieve blood pressure goals. Piramal Pharma Solutions’ robust CDMO capabilities and George Medicines’ commitment to developing innovative treatments have made this breakthrough possible. The collaboration demonstrates the importance of partnerships in advancing medical innovation and improving patient outcomes. With WIDAPLIK now approved, patients with hypertension can expect a more effective and convenient treatment option.
Nimulid forms a powerful alliance with the Patna Pirates for the upcoming Season 12 of the Pro Kabaddi League.
Mankind Pharma’s Nimulid Strong has partnered with the Patna Pirates as the Official Pain Relief Partner for Pro Kabaddi League Season 12. This partnership aligns the brand’s powerful pain relief formula with the intense physical demands of kabaddi, a sport known for sudden pulls, rapid twists, and heavy tackles that strain the neck and body. Nimulid Strong stands out in the topical pain relief market with a 2.32% diclofenac concentration, double the standard 1.16% found in most products.
The brand’s formula provides relief in just 2 minutes, making it ideal for players who need instant recovery. Nimulid Strong is available in gel and spray formats, targeting neck pain from intense kabaddi movements. The gel format provides deep-penetrating, long-lasting relief, while the spray format offers on-the-go convenience. In its first year, the brand has sold around 20 lakh gel units and 10 lakh spray units, demonstrating its remarkable market performance.
Mr. Joy Chatterjee, Vice President of Sales and Marketing at Mankind Pharma, emphasized that the partnership celebrates India’s indigenous sport while supporting athletes and everyday warriors who push through pain. The company plans to expand the brand’s offerings with innovative formats like balms, roll-ons, and tablets, reinforcing its commitment to effective and accessible pain relief solutions.
The topical pain relief market in India is valued at over ₹5,000 crore, and Nimulid Strong’s unique formula and quick action have positioned it as a leader in this market. The partnership with the Patna Pirates is a strategic move to increase brand awareness and reach a wider audience. With its powerful pain relief formula and convenient formats, Nimulid Strong is well-positioned to become a go-to solution for individuals seeking quick and effective pain relief.
The collaboration between Mankind Pharma and the Patna Pirates is a win-win for both parties, as it promotes the brand’s products while supporting the team’s athletes and celebrating India’s indigenous sport. As the Pro Kabaddi League Season 12 progresses, Nimulid Strong’s partnership with the Patna Pirates is likely to increase brand visibility and drive sales, further solidifying its position in the topical pain relief market.
Two Pharmaceutical Firms Collaborate on State-of-the-Art Oral Solid Dose Manufacturing Facility in Sellersville
Two pharmaceutical companies have partnered to open a dedicated Oral Solid Dose (OSD) form suite in Sellersville, Pennsylvania. The partnership aims to provide a state-of-the-art facility for the development and manufacturing of oral solid dose pharmaceuticals. The new facility will offer a range of services, including formulation development, clinical trial manufacturing, and commercial production.
The OSD form suite is designed to meet the growing demand for oral solid dose pharmaceuticals, which are the most common form of medication. The facility will be equipped with cutting-edge technology and staffed by experienced professionals with expertise in pharmaceutical development and manufacturing. The partnership between the two companies brings together their collective knowledge and experience in the pharmaceutical industry, allowing them to offer a comprehensive range of services to clients.
The new facility will provide a range of benefits to clients, including faster turnaround times, increased flexibility, and improved quality control. The facility will also be designed to meet the highest standards of regulatory compliance, ensuring that all products manufactured there meet the strictest quality and safety standards.
The partnership between the two companies is a significant development in the pharmaceutical industry, as it brings together two experienced players with a deep understanding of the needs of clients. The new facility will be an important addition to the region’s pharmaceutical infrastructure, providing a range of services and expertise that will support the development and manufacturing of oral solid dose pharmaceuticals.
The opening of the dedicated OSD form suite in Sellersville is also expected to have a positive impact on the local economy, creating new job opportunities and stimulating economic growth. The facility will be an important hub for pharmaceutical development and manufacturing in the region, and its opening is a significant milestone in the partnership between the two companies.
Overall, the partnership between the two pharmaceutical companies to open a dedicated OSD form suite in Sellersville is an exciting development in the pharmaceutical industry. The new facility will provide a range of benefits to clients, including faster turnaround times, increased flexibility, and improved quality control. The partnership is also expected to have a positive impact on the local economy, creating new job opportunities and stimulating economic growth. With its state-of-the-art technology and experienced staff, the new facility is well-positioned to meet the growing demand for oral solid dose pharmaceuticals.
Zydus Lifesciences announces the passing of Samir Desai, President of its Biologics business unit.
Samir Desai, the President of the Biologics Business Unit at Zydus Lifesciences, has unfortunately passed away. Although the exact circumstances of his death are not specified, his passing is a significant loss to the organization and the pharmaceutical industry as a whole.
As the President of the Biologics Business Unit, Samir Desai played a crucial role in shaping the company’s strategy and direction in the biologics sector. Zydus Lifesciences is a leading pharmaceutical company that develops and manufactures a range of products, including biologics, which are medicinal products derived from living organisms. Under Desai’s leadership, the company has made significant strides in the biologics space, with a focus on developing innovative and affordable treatments for patients.
Desai’s experience and expertise in the pharmaceutical industry were extensive, and his loss will be deeply felt by his colleagues and peers. He was a respected leader and a driving force behind the company’s growth and success in the biologics sector. His passing will undoubtedly leave a void in the organization, and it will be challenging to replace his knowledge, expertise, and vision.
The news of Desai’s passing has likely sent shockwaves through the pharmaceutical industry, and his colleagues and friends will be mourning his loss. Zydus Lifesciences will need to regroup and re-evaluate its strategy in the biologics sector, but for now, the focus will be on paying tribute to Desai’s memory and celebrating his contributions to the company and the industry.
It’s worth noting that the article from which this information is derived uses cookies for analytics, advertising, and to improve the site. By continuing to use the site, users agree to the use of these cookies. For more information on the site’s cookie policy and settings, users can refer to the relevant sections.
In conclusion, Samir Desai’s passing is a significant loss to Zydus Lifesciences and the pharmaceutical industry. His leadership and expertise in the biologics sector will be deeply missed, and his contributions to the company’s growth and success will be remembered and celebrated. As the company moves forward, it will be essential to find a way to build on Desai’s legacy and continue to drive innovation and growth in the biologics sector.
Mankind Pharma Limited receives counsel from Luthra and Luthra, EPAM Law Offices for establishing its Russian subsidiary.
Mankind Pharma, an Indian pharmaceutical company, has successfully incorporated a subsidiary in Russia. This process was facilitated by Luthra and Luthra Law Offices India, which provided comprehensive legal advice and guidance. The law firm played a crucial role in structuring the subsidiary, ensuring compliance with Russian regulations, and navigating the complexities of international sanctions.
Luthra and Luthra Law Offices India coordinated with Russian counsel to ensure a seamless incorporation process. The firm’s expertise in cross-border transactions and regulatory matters was instrumental in overcoming the challenges posed by international sanctions. The team advised Mankind Pharma on the optimal structure for the subsidiary, taking into account the prevailing regulatory landscape.
The transaction was led by Pradnesh Warke, a partner at Luthra and Luthra Law Offices India, who brought his expertise in corporate law and cross-border transactions to the table. He was supported by a team of experienced lawyers, including Ravi Raj Shekhar, a senior associate, and associates Devashree Kulkarni and Tanay Jha. Together, they worked closely with Mankind Pharma to ensure that all documentation and regulatory requirements were met, facilitating a smooth incorporation process.
The incorporation of a subsidiary in Russia is a significant milestone for Mankind Pharma, marking its expansion into a new market. The company’s decision to establish a presence in Russia reflects its commitment to growing its global footprint and increasing its access to new markets. Luthra and Luthra Law Offices India’s role in this process demonstrates the firm’s capabilities in handling complex cross-border transactions and its ability to navigate challenging regulatory environments.
The success of this transaction is a testament to the strong partnership between Mankind Pharma and Luthra and Luthra Law Offices India. The law firm’s expertise and guidance were essential in ensuring that the incorporation process was completed efficiently and effectively, despite the complexities posed by international sanctions. As Mankind Pharma continues to expand its global presence, the company can rely on Luthra and Luthra Law Offices India to provide expert legal advice and support.
Piramal Pharma Releases Its FY2025 Sustainability Report, Outlining a Comprehensive Decarbonization Strategy
Piramal Pharma Limited (PPL) has released its FY2025 Sustainability Report, which highlights the company’s progress in integrating responsible practices across its operations worldwide. The report is themed “Innovating Responsibly, Growing Sustainably” and demonstrates measurable progress across four strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
The company has made significant progress in various areas, including strengthening governance frameworks, accelerating decarbonization, advancing diversity and inclusion, and enhancing community impact through its CSR programs. Some key achievements include a 6% reduction in Scope 1 & 2 emissions, a 7.8% increase in renewable energy adoption, and a 90% recycling target for non-hazardous waste.
Piramal Pharma has also made significant strides in diversity and inclusion, with 30% women representation on the Board and 20% women in the global workforce. The company has also launched various initiatives to promote stakeholder centricity, including a women-led! skill development program and a partnership with the Life Sciences Sector Skill Development Council.
The company’s CSR initiatives have had a significant impact, with outreach to 112 aspirational districts and investments of ₹5.34 crore in initiatives such as school infrastructure upgrades, teacher training, and public health campaigns. Employee volunteering has also supported various community projects, including plantation drives, health awareness sessions, and community projects.
Nandini Piramal, Chairperson of Piramal Pharma Limited, stated that sustainability is a deliberate choice for the company and that they remain committed to innovating responsibly and growing sustainably for patients, communities, and the planet. The company’s commitment to sustainable growth is aligned with GRI standards, SASB, and UNGC frameworks, and the report demonstrates Piramal Pharma’s commitment to responsible capital allocation, sustainable operations, and impactful stakeholder engagement.
Some of the key statistics from the report include:
* 50% independent directors on the Board
* 30% women representation on the Board
* 26.5% of critical suppliers assessed on sustainability
* 36 regulatory inspections successfully completed
* 165 customer audits conducted globally
* 6% reduction in Scope 1 & 2 emissions
* 7.8% increase in renewable energy adoption
* 90% recycling target for non-hazardous waste
* 2.10 lakh kiloliters of freshwater conserved through water stewardship initiatives
* 2,000+ saplings planted
* 30% green cover maintained across Indian sites
Overall, Piramal Pharma’s FY2025 Sustainability Report demonstrates the company’s commitment to sustainability and responsible growth, and highlights its progress in various areas, including governance, diversity and inclusion, and community impact.
Alkem Laboratories Sees Varied Results as Stakeholders Raise Concerns and Assessment Criteria Evolve
Alkem Laboratories, a midcap company in the Pharmaceuticals & Biotechnology sector, has undergone an evaluation adjustment due to changes in its underlying trends. The company’s financial performance is mixed, with a year-over-year return of -7.52% and a modest profit increase of 4.9%. Despite this, the company’s net sales growth has averaged 9.38% annually over the last five years, with operating profit growth at 9.03%. However, the recent quarter’s results have shown flat performance, raising concerns about long-term growth potential.
Promoter confidence in the company appears to be decreasing, with a 2.09% decrease in their stake, which now stands at 53.04%. This decline may indicate concerns about the company’s future trajectory. On the other hand, Alkem Laboratories maintains a high management efficiency, with a return on equity (ROE) of 17.69% and a low debt-to-equity ratio of 0 times. This suggests that the company is being managed effectively, despite the challenges it faces.
The recent evaluation adjustment reflects the complexities of Alkem Laboratories’ market position and performance indicators. The company’s mixed financial performance, combined with the decline in promoter confidence, raises questions about its long-term growth potential. However, the company’s high management efficiency and low debt-to-equity ratio are positive indicators that suggest it may be able to navigate these challenges.
Overall, Alkem Laboratories is facing a complex market position, with both positive and negative indicators. The company’s mixed financial performance and declining promoter confidence are concerns, but its high management efficiency and low debt-to-equity ratio are positives. As the company continues to navigate these challenges, it will be important to monitor its performance and adjust expectations accordingly. With the latest evaluation adjustment, it is essential for investors to reassess the company’s potential and make informed decisions about their investments.
Agenus to host August 27 webcast, featuring significant immuno-oncology updates, BOT/BAL data release, preview of BATTMAN, progress on Zydus partnership, and spotlight on MiNK.
Agenus Inc., a leading immuno-oncology company, has announced an update to its virtual Stakeholder Briefing, which will take place on August 27, 2025, at 4:00 p.m. ET. The webcast will provide a strategic and financial overview of the company, as well as updates on its partnerships, clinical trials, and product pipeline. The program will feature speakers including Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus, and Richard M. Goldberg, MD, Chief Development Officer of Agenus.
The webcast will cover several key topics, including the company’s Zydus partnership, patient needs in colorectal cancer studies, recent clinical updates on its botensilimab and balstilimab programs, and an overview of the Phase 3 BATTMAN study in metastatic colorectal cancer. Additionally, there will be a spotlight on MiNK Therapeutics, a company in which Agenus has a significant stake.
Agenus is a leader in the development of immunological agents for the treatment of cancer. The company’s pipeline includes a range of antibody therapeutics, adoptive cell therapies, and adjuvants. Its lead product, botensilimab, is a multifunctional antibody designed to boost anti-tumor immune responses. Botensilimab has shown clinical responses in several metastatic cancers, and is being evaluated in combination with Agenus’ investigational PD-1 antibody, balstilimab.
The company has also developed balstilimab, a novel monoclonal antibody designed to block PD-1. Balstilimab has demonstrated clinical activity and a favorable tolerability profile in several tumor types. Agenus is headquartered in Lexington, MA, and has a global clinical operations footprint.
The webcast will conclude with a live Q&A session, and attendees can participate via a new virtual format. Pre-registration is not required, and the webcast link is available on the company’s website. Agenus cautions investors not to place undue reliance on forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from current expectations.
Biggest Global Pharma Firms of 2025: Ranking the Top 5
The pharmaceutical industry is a vital sector that produces life-saving medicines, vaccines, and treatments that improve global health. The top five largest pharmaceutical companies in the world, as of 2025, are Pfizer, Johnson & Johnson, AbbVie, Merck & Co., and Roche. These companies drive innovation in healthcare and supply essential drugs to the global market.
Pfizer remains the largest pharmaceutical company in 2025, with a revenue of $58.5 billion. Despite a decline in sales of pandemic-related products, Pfizer still grew by 7% in 2023, excluding COVID medicines. The company specializes in immunology, oncology, cardiology, neurology, and vaccines, and has made key moves such as acquiring Seagen Inc. to strengthen its oncology pipeline.
Johnson & Johnson ranks second, with a revenue of $54.8 billion. The company is known for its wide range of healthcare products and continues to perform strongly in pharmaceuticals. Its top medicines include Darzalex, Stelara, Tremfya, and Erleada, which treat multiple myeloma, autoimmune diseases, psoriasis, and prostate cancer.
AbbVie ranks third, with a revenue of $54.3 billion. However, its sales dipped due to the loss of exclusivity for Humira, once the world’s bestselling drug. The company is investing heavily in research and development and has made acquisitions such as ImmunoGen and Cerevel Therapeutics to strengthen its pipeline.
Merck & Co. ranks fourth, with a revenue of $53.6 billion. The company has a history of over 130 years and focuses on pharmaceuticals, vaccines, and animal health. Its top product, Keytruda, contributed nearly half of its pharma revenues, reaching $25 billion. The company is preparing for Keytruda’s patent expiry in 2028 and has made acquisitions such as Prometheus Biosciences and Harpoon Therapeutics to expand into immunology.
Roche rounds out the top five, with a revenue of $49.9 billion. The company has a history of over 128 years and focuses on oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Despite lower sales in COVID-related products, new drugs like Vabysmo grew rapidly, up 85% in 2023. The company is expanding into cardiometabolic diseases and inflammatory conditions through partnerships and acquisitions.
These top five pharmaceutical companies are driving innovation in healthcare and shaping the future of global medicine. They are investing heavily in research and development, making strategic acquisitions, and expanding their product portfolios to meet the evolving needs of the global market. As the pharmaceutical industry continues to evolve, these companies are well-positioned to remain leaders in the sector.
Garmin and Apollo HealthAxis strengthen their strategic partnership.
Garmin and Apollo HealthAxis have announced a deepening of their strategic collaboration. The partnership aims to reimagine Indian healthcare by integrating Garmin’s wearable technology with Apollo HealthAxis’s healthcare services.
The collaboration will focus on preventive healthcare, leveraging Garmin’s wearable devices to track users’ vital signs, physical activity, and other health metrics. Apollo HealthAxis will utilize this data to provide personalized health and wellness services, including consultations, diagnostics, and treatment plans.
By combining their expertise, Garmin and Apollo HealthAxis seek to promote proactive healthcare management, enabling individuals to take control of their health and wellbeing. The partnership will also facilitate the development of customized wellness programs, tailored to meet the specific needs of users.
Garmin’s wearable devices, such as smartwatches and fitness trackers, will play a crucial role in the collaboration. These devices will collect data on users’ health and fitness metrics, including heart rate, sleep patterns, and physical activity levels. This data will be shared with Apollo HealthAxis, allowing their healthcare professionals to gain a more comprehensive understanding of users’ health needs.
Apollo HealthAxis will then use this data to provide personalized health recommendations, consultations, and interventions. The organization’s healthcare experts will work closely with users to develop customized wellness plans, addressing specific health concerns and goals.
The deepened collaboration between Garmin and Apollo HealthAxis highlights the growing importance of preventive healthcare in India. By leveraging wearable technology and healthcare services, the partnership aims to empower individuals to take a more proactive approach to their health and wellbeing.
The integration of Garmin’s wearable devices with Apollo HealthAxis’s healthcare services has the potential to transform the Indian healthcare landscape. By providing personalized, data-driven healthcare solutions, the partnership seeks to improve health outcomes, enhance user experience, and reduce healthcare costs.
Overall, the strategic collaboration between Garmin and Apollo HealthAxis represents a significant step forward in the pursuit of innovative, patient-centric healthcare solutions in India. As the partnership continues to evolve, it is likely to have a profound impact on the country’s healthcare ecosystem, enabling individuals to lead healthier, more fulfilling lives.
Market Outlook for Generic Drugs in Saudi Arabia 2025-2033: Key Players Include Teva, Viatris, Sandoz, Sun Pharma, Cipla, Aurobindo Pharma, Lupin, Hikma Pharma, STADA Arzneimittel, and Dr. Reddy’s Labs.
The Saudi Arabia Generic Drugs Market is expected to grow significantly, reaching US$ 8.11 billion by 2033, with a Compound Annual Growth Rate (CAGR) of 8.02% from 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to reduce pharmaceutical expenditure, and growing awareness of cost-effective alternatives. The market is also driven by local manufacturing and government support for generics.
The demand for generic medications in Saudi Arabia is increasing rapidly, driven by the government’s attempts to reduce reliance on imported branded medicines and lower healthcare spending. The Saudi Food and Drug Authority (SFDA) has simplified the process of generic approvals, encouraging local and foreign manufacturers to increase their generic offerings.
Key growth drivers in the Saudi Arabia Generic Drugs Market include government support and cost containment initiatives, increasing incidence of chronic diseases, and growing local production capability. The government has focused on making healthcare more affordable through greater generic drug promotion, and initiatives such as the “Procedure to deal with patents when registering generic products in SFDA” have been introduced to facilitate the growth of the generic drug market.
However, the market also faces challenges, including public perception and brand loyalty, as well as regulatory and quality control complexity. Despite these challenges, the market is expected to continue growing, driven by the increasing demand for cost-effective generic drugs.
The report provides an in-depth analysis of the Saudi Arabia Generic Drugs Market, including market trends, forecast, and key players analysis. The market is segmented by type, route of administration, therapeutic area, distribution channel, and region. Key players in the market include Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz Group AG, and Sun Pharmaceutical Industries Ltd.
The report also highlights the growing trend of online generic drugs in Saudi Arabia, with digital platforms and e-pharmacies facilitating easier price comparisons and prescription-based generics ordering for consumers. The online generic drug segment is expected to receive robust traction, particularly in urban regions such as Riyadh and Jeddah.
In terms of therapeutic areas, the report highlights the growing demand for generic drugs in areas such as respiratory, oncology, and infectious diseases. The report also provides an analysis of the regulatory framework of generic drugs in Saudi Arabia, including the role of the SFDA and the challenges faced by manufacturers in complying with regulatory requirements.
Overall, the Saudi Arabia Generic Drugs Market is expected to continue growing, driven by government support, increasing demand for cost-effective generic drugs, and growing local production capability. The report provides a comprehensive analysis of the market, including key trends, challenges, and opportunities, and is a valuable resource for companies looking to enter or expand their presence in the Saudi Arabian generic drugs market.
India is on the cusp of becoming the globe’s premier healthcare hub.
Dr. Prathap C Reddy, Founder-Chairman of Apollo Hospitals and Chancellor of Apollo University, has expressed his confidence that India is on the verge of becoming the world’s healthcare capital. He made this statement while addressing students and faculty at Apollo Knowledge City in Chittoor. Dr. Reddy highlighted India’s growing presence in the global medical field, citing the fact that nearly 10% of doctors in the US and up to 30% in the UK are of Indian origin. This, he believes, is a testament to the talent and dedication of Indian medical professionals.
Dr. Reddy emphasized the potential of India’s youth to make the country a global healthcare hub, provided they receive proper training and guidance. He recalled the pioneering role of Apollo Hospitals in cardiology, including complex surgeries and heart transplants, which has eliminated the need for patients to travel abroad for treatment. He also mentioned Apollo’s efforts in introducing advanced technologies, such as proton therapy for cancer treatment, in cities like Delhi and Hyderabad.
Dr. Reddy stressed that healthcare encompasses not only medicine but also technology, preventive care, and emergency services. He noted that Apollo University is integrating engineering education to drive medical innovations, underscoring the importance of a multidisciplinary approach to healthcare. The event was attended by various dignitaries, including Apollo University Vice Chancellor Dr. H Vinod Bhat, Registrar Prof M Potharaju, and a large gathering of students.
Dr. Reddy’s vision for India as a global healthcare capital is built on the country’s existing strengths in medical talent and innovation. With the right support and guidance, he believes that India’s youth can play a crucial role in making this vision a reality. The event served as a motivational platform for students and faculty, encouraging them to strive for excellence in the field of healthcare and contribute to India’s emergence as a global healthcare hub. Overall, Dr. Reddy’s speech highlighted the vast potential of India’s healthcare sector and the importance of investing in the country’s youth to achieve this goal.
Sikkim High Court Overturns GST Ruling, Restores Rs. 59 Lakh Budgetary Support to Zydus Wellness
The High Court of Sikkim has recently overturned a decision by the GST authorities to deny Zydus Wellness budgetary support of ₹59.44 lakh. The court ruled that the rejection was “untenable in law” and went against established judicial precedent. The GST authorities had rejected Zydus Wellness’ claim for budgetary support under the Scheme of Budgetary Support to Eligible Industrial Units in the North Eastern Region and Himalayan States, 2017. The Assistant Commissioner of Central Goods and Services Tax had concluded that the eligible support was “in the negative” and therefore, the company was not entitled to any benefit.
Zydus Wellness challenged this decision under Article 226 of the Constitution, arguing that the issue had already been settled by a Division Bench of the same High Court in a previous case, Glenmark Pharmaceuticals Limited v. Union of India (2024). In that case, the court had relied on a decision by the Jammu & Kashmir and Ladakh High Court, which clarified that budgetary support claims must be calculated on the basis of monthly tax payments through the cash ledger, rather than on a quarterly basis as interpreted by the authorities.
The High Court of Sikkim set aside the order dated 27 June 2022 passed by the Assistant Commissioner of CGST and directed that Zydus Wellness’ claim be reconsidered in line with the principles laid down in the Glenmark Pharmaceuticals and Coromandel International rulings. The court’s decision is a significant victory for Zydus Wellness, which will now be eligible to receive the budgetary support of ₹59.44 lakh.
The case, Zydus Wellness-Sikkim vs The Assistant Commissioner, was heard by Justice Meenakshi Madan Rai, who delivered the judgment on 11 August 2025. The counsel for the appellant, Mr. Mayank Jain, and the counsel for the respondent, Ms. Sangita Pradhan, presented their arguments in the case. The court’s decision has been cited as 2025 TAXSCAN (HC) 1725, and the case number is WP(C) No.10 of 2024. The ruling provides clarity on the calculation of budgetary support claims and will have implications for other companies operating in the North Eastern Region and Himalayan States.
Pharma’s quest for expansion: Reaching out to the consumer’s doorstep
Several Indian pharmaceutical companies, including Cipla, Glenmark, Lupin, and Mankind Pharma, have demerged their consumer healthcare businesses to focus on growth and expansion. This trend is also being seen globally, with companies like GlaxoSmithKline, Johnson and Johnson, and Sanofi separating their consumer healthcare divisions. The rationale behind this strategy is to create a separate entity that can operate with a more agile and fast-moving consumer goods (FMCG) mindset, allowing for more focused marketing and advertising efforts.
According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company’s objective was to create a separate division for its over-the-counter (OTC) brands, which require a different environment, culture, and talent compared to prescription brands. The company had previously run its OTC business like its prescription business, but found that it was not effective. Juneja explains that some prescription brands can be transitioned to the consumer healthcare business within the regulatory framework, but everything should be different, including management, to stay focused and agile.
Subhakanta Bal, Managing Director and Head of Healthcare and Consumer at Rothschild & Co, notes that there are commonalities between consumer healthcare and the core prescription-driven business, but also differences. For example, consumer healthcare requires a more FMCG-like mindset, with a focus on marketing and advertising to drive sales. Bal observes that pharma companies often bring in FMCG veterans to run their consumer healthcare divisions, and that a separate entity can be more “fit for purpose”.
The pursuit of growth is the key reason behind the consumer healthcare demerging trend, according to Vishal Manchanda, Senior Vice-President at Systematix Group. Pharma companies are developing a second platform for growth, given the challenges in the domestic branded business and global uncertainties. However, it’s not an easy task, with intense competition from store-owned brands and pressure on prices.
The demerging of consumer healthcare businesses is expected to lead to better value realization, potentially through listing, as FMCG businesses in India trade at a higher value than domestic formulation businesses. Internationally, big pharma companies have separated or exited consumer healthcare to focus on innovation, but in India, the trend is driven by the need for right managerial talent, marketing, and advertising to ensure success. As the Indian pharmaceutical industry continues to evolve, the demerging of consumer healthcare businesses is likely to be a key strategy for growth and expansion.
Does Enanta’s Lawsuit and PADCEV Trial’s Positive Outcomes Alter Pfizer’s (PFE) Investment Storyline?
Pfizer, a leading pharmaceutical company, is facing a crucial period as it navigates through patent litigation and promising cancer trial results. Enanta Pharmaceuticals has initiated a lawsuit against Pfizer in the European Unified Patent Court, alleging infringement of a newly granted COVID-19 antiviral patent. This lawsuit adds to the existing risks faced by Pfizer, including patent expirations and tightening regulatory policies.
However, Pfizer has announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer patients not eligible for cisplatin-based therapy. This combination of promising cancer trial results and fresh EU patent litigation marks a pivotal period as Pfizer’s innovation meets potential hurdles in its COVID-19 portfolio.
The successful PADCEV and KEYTRUDA trial could update Pfizer’s outlook, as it underpins the company’s opportunity to offset potential revenue loss from patent expirations with strong new clinical trial outcomes. These results not only reinforce confidence in Pfizer’s oncology pipeline but also support a key catalyst, successful new product launches that could help bridge the gap created by expiring exclusivity on high-revenue drugs.
Pfizer’s outlook anticipates $59.7 billion in revenue and $13.2 billion in earnings by 2028, reflecting a 2.2% annual revenue decline and a $2.5 billion increase in earnings from the current $10.7 billion. Some analysts see regulatory hurdles and expiring patents as constraining, while others expect revenues to fall to $56.1 billion by 2028.
Investors should stay alert as legal challenges could escalate, and new patent litigation may impact forecasts. The article emphasizes the importance of considering alternative viewpoints and exploring other perspectives on Pfizer’s future. The company’s forecasts yield a $28.77 fair value, a 11% upside to its current price. Despite the challenges, Pfizer’s innovation and promising cancer trial results could energize its growth story, making it an attractive investment opportunity.
Overall, Pfizer’s future is uncertain, with both opportunities and risks on the horizon. Investors should carefully consider the company’s outlook, taking into account the potential impact of patent litigation, regulatory hurdles, and promising cancer trial results. By analyzing the company’s forecasts and considering alternative viewpoints, investors can make informed decisions about their investment in Pfizer.
Apollo Hospital reaches milestone of 600 successful pediatric liver transplants, commemorated with book release, as reported by The Week.
Two doctors from Apollo Hospital in New Delhi, Dr. Smita Malhotra and Dr. Anupam Sibal, have authored a book titled “Transplanting Hope” to commemorate the hospital’s 600th pediatric liver transplant. The book is an anthology of 25 stories that showcase the grit, courage, and perseverance of children facing life-threatening liver diseases. Each story captures the emotional battles, medical challenges, and moments of hope that define the journey of these young patients.
The book has a foreword by Indian cricket coach Gautam Gambhir, who praises the authenticity and emotional depth of the stories. The authors aim to go beyond statistics and clinical facts to portray the human spirit that transforms despair into determination. The book highlights the strength and resilience of the children and their families, who have fought against all odds to overcome their medical challenges.
According to Dr. Anupam Sibal, the book is a testament to the power of medicine, humanity, courage, and hope. He emphasizes that medicine is not just about science, but also about the human spirit and the sacrifices made by families. Dr. Smita Malhotra adds that while the book celebrates the triumphs, it also acknowledges the heartbreaks and setbacks that remind them of the need to keep advancing and fighting for better outcomes.
The hospital’s Managing Director, P Shivakumar, notes that the milestone of 600 pediatric liver transplants is a matter of pride not just for Apollo Hospitals, but for Indian healthcare as a whole. The hospital’s mission has been to give children a chance at life and families a chance at hope since its first successful pediatric liver transplant in 1998.
The book has been praised by Dr. Neerav Goel, Chief Liver Transplant Surgeon, who says that it beautifully captures the essence of their daily work, celebrating medical breakthroughs while honoring the emotional journeys behind them. Gautam Gambhir’s foreword commends the book as a collection of 25 sagas of hope, courage, and human perseverance against all odds, noting that each story is real and authentic, with no scripted or grey areas. Overall, “Transplanting Hope” is a powerful and inspiring book that showcases the human spirit and the power of medicine to transform lives.
Piramal Pharma has inaugurated a US-based facility for the production of Oral Solid Dosage (OSD) formulations, as reported by ICICI Direct.
Piramal Pharma has announced the opening of its new facility in the USA for the production of Oral Solid Dosage (OSD) forms. This move is expected to enhance the company’s capabilities in the global pharmaceutical market.
The new facility, located in the United States, will enable Piramal Pharma to leverage its expertise in OSD production to cater to the growing demands of the global pharmaceutical industry. The company has invested significantly in this facility, which is equipped with state-of-the-art technology and equipment to ensure high-quality production.
Piramal Pharma’s decision to open a facility in the USA is a strategic one, as it will allow the company to strengthen its presence in the North American market. The USA is one of the largest pharmaceutical markets in the world, and having a local production facility will enable Piramal Pharma to better serve its customers in the region.
The facility will produce a range of OSD products, including tablets, capsules, and other solid oral dosages. Piramal Pharma has a strong track record of producing high-quality pharmaceutical products, and the new facility will adhere to the same stringent quality standards. The company’s expertise in OSD production, combined with its commitment to quality, will enable it to deliver products that meet the exacting standards of the global pharmaceutical industry.
The opening of the new facility is also expected to create new job opportunities in the region. Piramal Pharma is committed to contributing to the local economy and has plans to hire skilled personnel to work at the facility. This will not only benefit the local community but also enhance the company’s capabilities in the region.
Piramal Pharma’s expansion into the USA is a significant milestone for the company, and it underscores its commitment to becoming a leading global pharmaceutical player. The company’s strategic decision to open a facility in the USA is expected to drive growth and expansion, and it will enable Piramal Pharma to better serve its customers in the North American market.
Overall, the opening of Piramal Pharma’s new facility in the USA is a positive development for the company and the global pharmaceutical industry. It highlights the company’s commitment to quality, innovation, and customer satisfaction, and it is expected to drive growth and expansion in the years to come. With its strong track record of producing high-quality pharmaceutical products, Piramal Pharma is well-positioned to become a leading player in the global pharmaceutical market.
PFE transformation as a market catalyst fuels Institutional Tactics with a Liquidity Pulse, revolutionizing asset management strategies.
The key findings for Pfizer Inc. (NYSE: PFE) indicate a strong sentiment in the near and mid-term, but a weak long-term outlook. The analysis reveals no clear price positioning signal, but the upside opportunity looks excellent as long as the converted support holds. The current price is $25.82, with signals identified at $21.21, $23.10, $24.87, and $25.82.
The institutional trading strategies are generated by AI models, which provide three distinct trading strategies tailored to different risk profiles and holding periods. These strategies incorporate sophisticated risk management parameters to optimize position sizing and minimize drawdown risk.
The multi-timeframe signal analysis provides a breakdown of the signal strength and support and resistance signals for different time horizons. In the near-term (1-5 days), the signal strength is strong, with a support signal at $25.63 and a resistance signal at $25.87. In the mid-term (5-20 days), the signal strength is also strong, with a support signal at $25.56 and a resistance signal at $25.92. However, in the long-term (20+ days), the signal strength is weak, with a support signal at $23.10 and a resistance signal at $24.87.
The AI-generated signals for PFE are represented by different colors, with blue indicating the current price, red indicating resistance, and green indicating support. The analysis suggests that positive sentiment is prevailing, and investors can use the current signals for positioning and risk parameters. Overall, the analysis provides a comprehensive view of the market sentiment and trends for Pfizer Inc., helping investors make informed decisions about their trading strategies.
It is essential to note that the long-term outlook is weak, which may indicate a potential shift in the market sentiment. However, the near and mid-term strong sentiment could provide excellent upside opportunities if the converted support holds. Investors should carefully consider the risk management parameters and position sizing to minimize drawdown risk and optimize their trading strategies.
Natco Pharma files lawsuit against Novo Nordisk in Delhi courts regarding intellectual property dispute over Semaglutide.
Natco Pharma, an Indian pharmaceutical company, has filed a lawsuit against Novo Nordisk, a Danish multinational pharmaceutical company, in a Delhi court over intellectual property rights related to semaglutide. Semaglutide is a medication used to treat type 2 diabetes and has shown significant potential in the treatment of obesity.
Natco Pharma is seeking to launch its own version of semaglutide in the Indian market, which is expected to be a significant opportunity for the company. The Indian firm hopes to be a major player in the market when it forms next year, as the demand for semaglutide is expected to increase rapidly.
Novo Nordisk currently holds the patent for semaglutide and has been marketing it under the brand name Ozempic. However, Natco Pharma claims that its own version of the medication does not infringe on Novo Nordisk’s patent, and the company is seeking a declaration from the court to this effect.
The lawsuit is seen as a significant development in the Indian pharmaceutical industry, where generic versions of popular medications are in high demand. Natco Pharma’s move is expected to be closely watched by other Indian pharmaceutical companies, which may also be looking to launch their own versions of semaglutide.
The outcome of the lawsuit is uncertain, and it may take several months or even years to resolve. However, if Natco Pharma is successful in its claim, it could pave the way for other Indian companies to launch their own versions of semaglutide, which could lead to increased competition and lower prices for the medication in the Indian market.
Novo Nordisk has not commented on the lawsuit, but the company has been actively defending its patent for semaglutide in other countries. The Danish company has been facing challenges from other generic manufacturers, and the lawsuit in India is just the latest development in this ongoing saga.
The Indian market for semaglutide is expected to be significant, with the country having a large population of people with type 2 diabetes and obesity. The demand for effective treatments for these conditions is high, and companies like Natco Pharma are looking to capitalize on this demand by launching their own versions of semaglutide.
Overall, the lawsuit between Natco Pharma and Novo Nordisk is a significant development in the Indian pharmaceutical industry, and the outcome will be closely watched by other companies and stakeholders. The case has the potential to shape the future of the semaglutide market in India and could have implications for the broader pharmaceutical industry.
Work Halts at David Werner’s Conversion of Metro Loft’s Pfizer Headquarters
A suspected fire at the former Pfizer headquarters in Manhattan, currently under construction for a residential conversion, prompted a response from authorities. The incident occurred at 235 East 42nd Street, where Nathan Berman’s Metro Loft and David Werner are working on the largest office-to-residential conversion in New York City. The construction site was temporarily halted, with hundreds of workers waiting on the sidewalk, while the fire department investigated the situation.
According to eyewitness accounts and videos, smoke was seen coming from the construction site, leading to the New York Fire Department being called. However, no actual fire was found, and no damage was reported. Work resumed after a brief investigation, with the construction crew member stating that work was halted for about 20 minutes.
The conversion project aims to transform the former Pfizer headquarters into approximately 1,500 rental units, including a mix of luxury rentals and affordable housing through the 467a tax abatement program. The developers have secured significant financing for the project, including a record $700 million construction loan from Madison Realty Capital in May. Additionally, Northwind Group provided a $75 million loan for the property at 219 East 42nd Street and a further $135 million in January.
The combined property will feature over 100,000 square feet of amenities and 30,000 square feet of retail space. Construction is expected to be completed by the last quarter of 2027. Nathan Berman’s Metro Loft and David Werner’s joint venture have been working on the project, with Werner owning the leasehold of the larger building and having purchased the smaller building in partnership with Alexandria Real Estate Equities before buying out the real estate investment trust.
The project has been making progress, with the developers navigating several rounds of financing to bring the massive undertaking to fruition. The conversion of the former Pfizer headquarters is a significant undertaking, and its completion is anticipated to bring a new wave of residential units to the Midtown area. With the project’s expected completion date and the significant financing secured, the developers are on track to deliver a unique and extensive residential offering in Manhattan.
Apollo remains poised for consistent growth in earnings.
According to a report by Reliance Securities, Apollo Hospitals is poised for significant growth and expansion in the future. The hospital chain is expected to benefit from several key factors, including the expansion of its bed capacity, an increase in international patient inflows, and a focus on specialty-led growth. These strategic initiatives are expected to drive revenue and profitability for the company.
In addition to these growth drivers, Apollo Hospitals’ subsidiary, HealthCo, is also on track to achieve cost efficiencies and break even digitally. This is expected to further enhance the company’s profitability and competitiveness in the market. The report by Reliance Securities highlights the potential for Apollo Hospitals to unlock value through various means, including the merger with Keimed and the listing of its pharmacy business.
The report notes that Apollo Hospitals has resilient margins and is experiencing improving profitability, which positions the company well for steady earnings expansion. The strategic levers mentioned earlier, including the Keimed merger and pharmacy business listing, add further upside potential to the company’s growth prospects.
Overall, the report suggests that Apollo Hospitals is well-placed to continue its growth trajectory, driven by a combination of strategic initiatives and value-unlocking opportunities. The company’s focus on expanding its bed capacity, increasing international patient inflows, and driving specialty-led growth is expected to drive revenue and profitability, while the cost efficiencies and digital breakeven achieved by HealthCo will further enhance the company’s competitiveness.
With its strong fundamentals and growth prospects, Apollo Hospitals is expected to continue to deliver steady earnings expansion, making it an attractive investment opportunity. The report by Reliance Securities provides a positive outlook for the company, highlighting its potential for long-term growth and value creation. As the healthcare industry continues to evolve, Apollo Hospitals is poised to remain a leading player, driven by its strategic initiatives and commitment to delivering high-quality patient care.
Makers of generic drugs agree to pay 71 million dollars to settle allegations of price-fixing.
Glenmark Pharmaceuticals Inc. USA and Pfizer Inc., along with its generic-drug unit Greenstone LLC, have reached a settlement agreement to resolve price-fixing claims brought by direct purchasers of generic drugs. According to the terms of the agreement, Glenmark Pharmaceuticals will pay approximately $38 million, while Pfizer and Greenstone will pay around $33 million.
The settlement is the latest development in a long-running dispute over allegations of price-fixing in the generic drug market. The direct purchasers, who include companies that buy generic drugs directly from manufacturers, had accused several major pharmaceutical companies, including Glenmark and Pfizer, of colluding to artificially inflate prices.
By settling the claims, Glenmark and Pfizer are able to avoid the uncertainty and potential risks associated with litigating the matter in court. The settlement agreement is expected to bring closure to the dispute and provide compensation to the direct purchasers who were affected by the alleged price-fixing scheme.
The case highlights the ongoing scrutiny of the pharmaceutical industry, particularly with regards to the pricing of generic drugs. Generics are copycat versions of brand-name drugs that are designed to be more affordable, but some manufacturers have been accused of exploiting their market power to drive up prices.
Law360, a leading source of legal news and analysis, has been closely following the case and providing updates on the latest developments. With its comprehensive coverage of the pharmaceutical industry and antitrust law, Law360 is an essential resource for professionals who need to stay up-to-date on the latest trends and developments.
In addition to its daily news coverage, Law360 offers a range of features, including expert analysis, mobile apps, and advanced search functionality. Subscribers can access a vast archive of articles, as well as real-time alerts and judge information. With a free 7-day trial, readers can experience the benefits of Law360’s comprehensive coverage and expert analysis for themselves.
Kiran Mazumdar-Shaw of Biocon calls for sweeping changes to accelerate the transition of innovations from laboratories to the market.
On India’s 79th Independence Day, Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Biocon Biologics, welcomed Prime Minister Narendra Modi’s emphasis on self-reliance, innovation, and reform. Shaw noted that Modi’s vision extends beyond self-reliance to making India “globally competitive” through innovation that delivers affordability. She also highlighted the importance of GST reforms to reduce the cost of essentials, which would be a significant step towards making products more affordable.
Shaw agreed with Modi’s message to the pharmaceutical industry, emphasizing the need to invest in research and cutting-edge technologies. She stressed that the sector requires regulatory reforms to enable innovation, citing the lengthy and costly journey from “lab to market” as a key bottleneck. Shaw explained that the current regulatory framework makes investments in innovative molecules “high risk” and deters funding. She emphasized the importance of developing homegrown solutions rather than relying on products developed overseas.
Shaw cited China as an example of how regulatory ecosystems can drive domestic innovation. She urged regulators to play a crucial role in supporting research and innovation in India, enabling the country to take its innovations to the world. On the potential impact of Modi’s announcements on global ratings agencies, Shaw took a broader view, noting that the Independence Day speech is not a budget speech. However, she expressed hope that the “very strong intent for regulatory reforms” could pave the way for broader reform momentum.
Shaw’s comments highlight the need for urgent regulatory changes in the pharma sector to realize the vision of self-reliance and innovation. The industry requires bold regulatory reforms to shorten the journey from lab to market, enabling investments in innovative molecules and driving domestic innovation. With the right regulatory framework, India can develop homegrown solutions, reduce its reliance on overseas products, and become a globally competitive player in the pharmaceutical industry. Overall, Shaw’s remarks emphasize the importance of regulatory reforms in supporting India’s vision of self-reliance and innovation, and the need for urgent action to drive growth and development in the pharma sector.
Apollo Hospitals in India plans to double its investments in artificial intelligence after surpassing profit expectations.
Apollo Hospitals, one of India’s largest private healthcare providers, has announced plans to double its investments in artificial intelligence (AI) over the next two years. The move is aimed at improving patient outcomes, enhancing operational efficiency, and expanding its reach in the country’s growing healthcare market. The company’s decision to boost AI investments comes on the back of strong financial performance, with its quarterly profit beating analyst estimates.
Apollo Hospitals reported a net profit of ₹134.26 crore ($18.2 million) for the quarter ended December, exceeding analyst expectations of ₹128.4 crore ($17.4 million). The company’s revenue from operations rose 18% year-on-year to ₹2,441.6 crore ($331.5 million), driven by growth in its hospital and pharmacy segments. The strong financial performance has given the company the confidence to accelerate its digital transformation journey, with AI playing a key role in its strategy.
Apollo Hospitals has already implemented AI-powered solutions in various aspects of its operations, including diagnosis, patient engagement, and operational efficiency. The company has partnered with various technology startups and companies, including Microsoft and IBM, to develop and implement AI-based solutions. With its enhanced AI investments, Apollo Hospitals aims to further leverage machine learning, natural language processing, and computer vision to improve patient care and experience.
The company plans to deploy AI-powered chatbots to enhance patient engagement and provide personalized healthcare services. Additionally, Apollo Hospitals will use AI to analyze medical data and develop predictive models to improve diagnosis and treatment outcomes. The company also aims to use AI to optimize operational efficiency, streamline clinical workflows, and reduce costs.
Apollo Hospitals’ decision to double its AI investments reflects the growing trend of adopting digital technologies in India’s healthcare sector. The company’s focus on AI is expected to not only improve patient outcomes but also provide a competitive edge in the market. With the Indian government’s push for digital healthcare and the increasing demand for quality healthcare services, Apollo Hospitals is well-positioned to leverage AI and other digital technologies to drive growth and expansion. Overall, the company’s strong financial performance and plans to boost AI investments indicate a promising future for Apollo Hospitals and the Indian healthcare sector as a whole.
CDSCO Panel Approves Sun Pharma’s Phase IV Clinical Trial for Dual Release Pantoprazole in Treating Gastroesophageal Reflux Disease (GERD)
Sun Pharma, a leading pharmaceutical company, has announced that its Phase IV study on dual release pantoprazole for the treatment of Gastroesophageal Reflux Disease (GERD) has received acceptance from the Central Drugs Standard Control Organization (CDSCO) panel. This milestone marks a significant step forward in the development of a new treatment option for patients suffering from GERD.
GERD is a chronic condition characterized by the backflow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and difficulty swallowing. Pantoprazole is a proton pump inhibitor (PPI) that works by reducing the amount of acid produced in the stomach. The dual release formulation of pantoprazole developed by Sun Pharma is designed to provide both immediate and sustained release of the medication, offering enhanced efficacy and convenience for patients.
The Phase IV study, which was conducted in accordance with CDSCO guidelines, aimed to evaluate the safety and efficacy of dual release pantoprazole in patients with GERD. The study’s findings were presented to the CDSCO panel, which has now accepted the results. This acceptance is a crucial step towards obtaining regulatory approval for the new formulation.
The CDSCO panel’s acceptance of the study’s results is a testament to the rigor and quality of Sun Pharma’s research and development efforts. The company’s commitment to improving patient outcomes and addressing unmet medical needs is evident in its pursuit of innovative treatment options like dual release pantoprazole.
With this development, Sun Pharma is poised to bring a new treatment option to patients with GERD, offering them a potentially more effective and convenient way to manage their symptoms. The company’s expertise in formulation development and its strong regulatory capabilities have enabled it to navigate the complex regulatory landscape and achieve this milestone.
As the pharmaceutical industry continues to evolve, companies like Sun Pharma are at the forefront of innovation, driving progress in the development of new treatments and therapies. The acceptance of the Phase IV study on dual release pantoprazole by the CDSCO panel is a significant achievement, demonstrating Sun Pharma’s capabilities and commitment to delivering high-quality, effective treatments to patients.
Volini by Sun Pharma Introduces ‘Uparna’, a Groundbreaking Initiative for Devotees Traveling to Pandharpur
Sun Pharmaceutical Industries Limited, India’s leading pharmaceutical company, has launched a unique initiative through its pain relief brand, Volini. During the annual Pandharpur Wari pilgrimage in Maharashtra, one of the oldest and most significant spiritual journeys in the state, Volini introduced the “Volini Uparna”. This innovative product is a modern twist on the traditional Uparna, a multipurpose cloth worn by pilgrims over their shoulders, symbolizing comfort, resilience, and faith.
The Uparna has been redesigned to include a specially designed sleeve that holds Volini Gel, providing instant pain relief for sore muscles and joints. This allows pilgrims to access pain relief on the go, making their 21-day, 250-kilometer journey more comfortable. The initiative was launched at Pirachi Kuroli, a key rest point along the pilgrimage route, where local residents and the Volini team distributed the Uparnas to pilgrims.
This effort is an extension of Volini’s long-standing tradition of supporting the Warkaris, the pilgrims who undertake the Pandharpur Wari journey, through on-ground pain relief camps. The Volini Uparna reflects the brand’s promise of “No Time for Pain” and positions Volini as a meaningful cultural companion, rather than just a pain relief solution. By incorporating its core product into a culturally significant item, Sun Pharma has demonstrated a deep understanding of consumer needs and cultural heritage.
The Volini Uparna is an innovative example of how a brand can blend tradition and utility to create a meaningful and functional product. It showcases Volini’s commitment to providing pain relief solutions that are both effective and culturally relevant. With over three million pilgrims participating in the Pandharpur Wari each year, the Volini Uparna has the potential to make a significant impact on the lives of those undertaking this spiritual journey. By reimagining a traditional item with a modern twist, Volini has created a unique and memorable brand experience that is likely to resonate with consumers and reinforce its position as a leader in the Indian pharmaceutical industry.
Fortis acquires Shrimann hospital in a massive Rs 462 crore deal
Fortis Healthcare has expanded its presence in Punjab by acquiring the 228-bed Shrimann Superspecialty Hospital for a consideration of Rs 462 crore. This marks the fifth hospital of Fortis in Punjab, with existing hospitals in Ludhiana, Mohali, and Amritsar. The acquired hospital is located on the Pathankot road and is built on a 3-acre land parcel. Fortis plans to expand the hospital’s capacity by adding 225 more beds, utilizing an adjacent 2.4-acre land chunk, taking the total bed count to over 450.
The hospital currently has a staff of 65 doctors and 1,000 support staff, which Fortis aims to retain while adding more specialists to the existing team. The medical charges for treatment will remain the same, ensuring continuity for patients. The hospital already has 25 specialty departments, including cardiac sciences, renal sciences, general and laparoscopic surgery, oncology, orthopaedics, neurosciences, and gastroenterology.
The hospital is equipped with advanced technologies such as PET Scan, fibroscan, and 28 dialysis beds, along with four advanced Operation Theatres and a Cath Lab. Fortis plans to add more advanced technologies to enhance patient care. The hospital is already empaneled with prominent government agencies, including the Ex-Servicemen Contributory Health Scheme (ECHS), Central Government Health Scheme (CGHS), Northern Railways, and the Central Armed Police Forces.
The promoters of Shrimann Hospital, Dr. V P Sharma, Dr. Harmeet Paul Singh, Dr. Rajeev Bhatia, and Dr. Ajay Marwaha, have welcomed the Fortis team, believing that the corporate environment will boost patient-centric care and infrastructural needs. The complete takeover process is expected to be completed within two months, as stated by Ashish Bhatia, Executive Vice-President of Fortis Healthcare. With this acquisition, Fortis Healthcare strengthens its presence in Punjab, providing high-quality healthcare services to a wider population.
Biocon Ltd (BOM:532523) Reports Strong Revenue Increase in Q1 2026 Earnings, Despite Margin Pressures, as Noted by GuruFocus on Investing.com Canada.
Biocon Ltd, an Indian biopharmaceutical company, reported its Q1 2026 earnings, showcasing strong revenue growth despite margin pressures. Here are the highlights from the earnings call:
Revenue Growth: Biocon Ltd posted a robust revenue growth of 23% year-over-year (YoY) to ₹2,441 crores ($310 million USD), driven by a strong performance across its business segments. The company’s biologics segment witnessed a significant growth of 31% YoY, while the small molecule segment grew by 18% YoY.
Margin Pressure: Despite the strong revenue growth, Biocon’s margins faced pressure due to higher research and development (R&D) expenses, which increased by 34% YoY to ₹351 crores ($45 million USD). The company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) margin contracted by 200 basis points to 24.1%, primarily due to the increased R&D expenses.
Operational Highlights: Biocon’s biologics segment received a significant boost with the European Commission’s approval for its biosimilar, Semglee (insulin glargine), in the European Union. The company also received approval from the US FDA for its Abraxane (paclitaxel) formulation. These approvals are expected to drive future growth for the company.
Guidance: Biocon Ltd maintained its fiscal year 2026 revenue growth guidance of 15-18% YoY, despite the short-term margin pressures. The company expects its biologics segment to drive growth, with a focus on expanding its global footprint.
Management Commentary: During the earnings call, the management team expressed confidence in the company’s long-term growth prospects, driven by its robust pipeline of biosimilars and small molecule products. They acknowledged the short-term margin pressures but emphasized that these are necessary investments for future growth.
Investor Takeaway: Biocon Ltd’s Q1 2026 earnings call highlights the company’s strong revenue growth trajectory, driven by its biologics segment. While margin pressures are a near-term concern, the company’s long-term growth prospects remain intact. Investors should focus on the company’s ability to execute on its pipeline and expand its global footprint, which will drive future growth and profitability. With a strong financial position and a robust pipeline, Biocon Ltd is well-positioned to navigate the challenges and opportunities in the biopharmaceutical industry.
ZDS-Varenicline, a smoking cessation medication developed by Zydus Lifesciences, receives approval from Health Canada, as reported by geneonline.com.
Zydus Lifesciences, a leading pharmaceutical company, has received approval from Health Canada for its smoking cessation drug, ZDS-Varenicline. This approval marks a significant milestone for the company, as it expands its presence in the Canadian market. ZDS-Varenicline is a generic version of Pfizer’s Chantix, which is a well-established medication for helping smokers quit.
ZDS-Varenicline is a prescription medication that works by reducing cravings for smoking and blocking the pleasurable effects of smoking. It is a selective alpha4beta2 nicotinic receptor partial agonist, which means it targets specific receptors in the brain that are involved in nicotine addiction. By activating these receptors, ZDS-Varenicline reduces the desire to smoke and helps individuals manage withdrawal symptoms.
The approval of ZDS-Varenicline by Health Canada is based on a comprehensive review of the drug’s safety and efficacy. Clinical trials have demonstrated that ZDS-Varenicline is effective in helping smokers quit, with studies showing that it can increase the chances of quitting by up to 50% compared to placebo. The medication has also been shown to be well-tolerated, with common side effects including nausea, insomnia, and headache.
Zydus Lifesciences’ approval for ZDS-Varenicline is a significant development for smokers in Canada who are looking to quit. Smoking is a major public health concern, and nicotine addiction is a significant challenge for many individuals. The availability of an affordable and effective generic medication like ZDS-Varenicline can help increase access to treatment and improve health outcomes for Canadians.
The company’s CEO, Sharvil Patel, expressed his excitement about the approval, stating that it reinforces the company’s commitment to providing high-quality and affordable medications to patients. Zydus Lifesciences has a strong presence in the Canadian market, and the approval of ZDS-Varenicline is expected to further expand its portfolio of medications.
In conclusion, the approval of ZDS-Varenicline by Health Canada is a significant achievement for Zydus Lifesciences, marking a major milestone in the company’s expansion into the Canadian market. The availability of this generic smoking cessation medication is expected to provide a more affordable treatment option for Canadian smokers, helping them to overcome nicotine addiction and improve their overall health. With its proven safety and efficacy, ZDS-Varenicline is poised to make a positive impact on public health in Canada.
Burn Pain Treatment Industry: Research, Therapies, and Key Players Including Johnson & Johnson, Mankind Pharma, Perrigo Company, Pfizer, Smith & Nephew, Sun Pharmaceutical, and Trio Li.
The burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. According to DelveInsight, the market is driven by the rising demand for effective pain management therapies for burn patients. Burn pain is a complex and debilitating condition that can have a significant impact on a patient’s quality of life. The market is witnessing the emergence of new therapies and treatments that aim to provide relief to patients suffering from burn pain.
The epidemiology of burn pain is a significant concern, with millions of people suffering from burn injuries every year. The majority of burn injuries are minor, but a significant proportion require medical attention. The global burn pain market is expected to grow due to the increasing incidence of burn injuries, particularly in developing countries where access to healthcare is limited.
Several companies are actively involved in the development of burn pain therapies, including Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, and Trio Life Sciences. These companies are investing heavily in research and development to create innovative treatments for burn pain. For example, Johnson & Johnson is developing a new topical cream for the treatment of burn pain, while Pfizer Inc. is working on a novel oral medication.
The current treatment landscape for burn pain is dominated by analgesics, such as morphine and fentanyl, which are often ineffective in managing severe burn pain. However, new therapies are emerging, including topical creams, dressings, and other innovative treatments. For instance, Mankind Pharma has developed a new dressing that helps to reduce pain and promote wound healing.
The burn pain market is expected to grow significantly over the next few years, driven by the increasing demand for effective pain management therapies. The market is also witnessing the emergence of new companies, such as Trio Life Sciences, which is developing a novel burn pain treatment. Sun Pharmaceutical Industries Ltd is also investing heavily in research and development to create innovative treatments for burn pain.
In conclusion, the burn pain market is a growing industry that is expected to expand due to the increasing incidence of burn injuries worldwide. The market is driven by the rising demand for effective pain management therapies, and several companies are actively involved in the development of new treatments. The current treatment landscape is dominated by analgesics, but new therapies are emerging, including topical creams, dressings, and other innovative treatments. As the market continues to grow, it is expected to provide relief to millions of patients suffering from burn pain worldwide.
CureVac and GSK have reached an agreement to settle their ongoing patent dispute with Pfizer and BioNTech.
CureVac, a German biotechnology company, and GlaxoSmithKline (GSK) have agreed to resolve a patent dispute litigation with Pfizer and BioNTech related to COVID-19 vaccine technology. The dispute centered on the use of messenger RNA (mRNA) technology, which is a key component of many COVID-19 vaccines, including those developed by Pfizer and BioNTech.
CureVac had alleged that Pfizer and BioNTech had infringed on its patents related to mRNA technology, which CureVac had developed prior to the pandemic. The company had sought damages and an injunction to prevent further use of its patented technology. Pfizer and BioNTech had denied any wrongdoing and argued that their vaccines did not infringe on CureVac’s patents.
The settlement marks the end of a long-running dispute between the companies. While the terms of the settlement have not been disclosed, it is likely that CureVac will receive some form of compensation or royalty payments from Pfizer and BioNTech. The settlement also removes a major uncertainty for the companies involved and allows them to focus on their ongoing vaccine development and distribution efforts.
Notably, BioNTech recently acquired a stake in CureVac, which likely played a role in the settlement. The acquisition gives BioNTech access to CureVac’s mRNA technology and expertise, and may have helped to facilitate a resolution to the patent dispute. The settlement is also a positive development for GSK, which had partnered with CureVac to develop a COVID-19 vaccine.
The resolution of the patent dispute is a significant development in the COVID-19 vaccine landscape. The use of mRNA technology has been a key factor in the rapid development and distribution of COVID-19 vaccines, and the settlement ensures that this technology can continue to be used to combat the pandemic. The settlement also highlights the complex and often contentious nature of patent disputes in the biotechnology industry, where intellectual property rights are highly valued and closely guarded.
Overall, the settlement between CureVac, GSK, Pfizer, and BioNTech is a positive development that removes a major obstacle to the ongoing development and distribution of COVID-19 vaccines. The settlement allows the companies involved to focus on their core business and underscores the importance of collaboration and cooperation in the fight against the pandemic.
The Steroid Implant Market is Expected to Experience Significant Growth, with Key Players such as Novartis, Allergan, and Pfizer Driving the Trend.
The Global Steroid Implant Market Study, conducted by HTF Market Intelligence, provides a comprehensive analysis of the market from 2025 to 2033. The report spans over 143 pages and covers the product and industry scope, market prognosis, and status. The market is expected to expand at a compound annual growth rate (CAGR) of 11.3% from 2025 to 2033, from USD 0.65 billion in 2025 to USD 1.51 billion by 2033.
The study segments the market by type, including dexamethasone, fluocinolone acetonide, prednisolone, methylprednisolone, and biodegradable. The market is also segmented by application, including ophthalmology, pain management, hormone replacement, chronic inflammation, and post-surgery care.
The dominant region in the market is North America, while the fastest-growing region is Asia-Pacific. The market trends include ocular, orthopedic, and dermatological applications, biodegradable and sustained-release platforms, personalized implant formulations, and drug-device combination therapies.
The market drivers include growth in chronic disease management, preference for long-acting therapies, advancements in biocompatible polymers, and a rise in outpatient/minimally invasive procedures. However, the market faces challenges such as implant rejection or infection risks, cost-intensive development, device failure or drug leakage issues, slow regulatory pathways, and the need for surgical expertise in some cases.
The market opportunities include expansion in veterinary applications, innovation in biosimilar implants, integration with remote monitoring, regulatory easing for targeted therapies, and partnerships with specialty clinics. Major companies profiled in the Steroid Implant Market include Allergan, Bayer, Novartis, Bausch Health, and Pfizer, among others.
The report provides a comprehensive analysis of the market, including in-depth analysis of market segments, regional analysis, and competitive analysis. It also provides insights into the market trends, drivers, challenges, and opportunities. The report is available for purchase, and a sample copy can be requested.
The key findings of the report include:
* The global Steroid Implant market is expected to expand at a CAGR of 11.3% from 2025 to 2033.
* The market is driven by growth in chronic disease management, preference for long-acting therapies, and advancements in biocompatible polymers.
* The market faces challenges such as implant rejection or infection risks, cost-intensive development, and slow regulatory pathways.
* The market opportunities include expansion in veterinary applications, innovation in biosimilar implants, and integration with remote monitoring.
Overall, the report provides a comprehensive analysis of the Global Steroid Implant Market, including market trends, drivers, challenges, and opportunities. It is a valuable resource for companies, investors, and researchers seeking to understand the market and make informed decisions.
Delhi High Court Grants Sun Pharma Reprieve by Restraining Use of BERIVITAL, BEZOLIC, and DOZE-30 Due to Trademark Infringement
The Delhi High Court has granted relief to Sun Pharma, a prominent pharmaceutical company, by barring the use of three trademarks – BERIVITAL, BEZOLIC, and DOZE-30 – due to trademark infringement. This decision is a significant victory for Sun Pharma, as it protects the company’s intellectual property rights and prevents other companies from using similar trademarks that could cause confusion among consumers.
The court’s ruling is based on the principle that a trademark is a unique identifier of a company’s products or services, and its use by another company can lead to confusion and dilution of the brand. In this case, the defendants were found to be using trademarks that were similar to Sun Pharma’s registered trademarks, which could have caused harm to the company’s reputation and business.
The Delhi High Court’s decision highlights the importance of protecting intellectual property rights, particularly in the pharmaceutical industry where brand reputation and trust are crucial. The court’s ruling sends a strong message to companies that attempt to infringe on registered trademarks, and it demonstrates the court’s commitment to upholding the law and protecting the rights of legitimate trademark owners.
The trademarks in question, BERIVITAL, BEZOLIC, and DOZE-30, are likely to be associated with specific products or therapies, and the court’s decision ensures that Sun Pharma’s products will not be confused with those of other companies. This decision also reinforces the importance of conducting thorough trademark searches and clearance procedures before launching new products or services.
Overall, the Delhi High Court’s decision is a significant win for Sun Pharma, and it demonstrates the company’s commitment to protecting its intellectual property rights. The ruling also serves as a reminder to other companies to respect the trademark rights of others and to take necessary steps to avoid infringement. By protecting its trademarks, Sun Pharma can maintain its brand integrity and continue to provide high-quality products to its customers without fear of confusion or dilution.
Pfizer’s CEO is set to attend a $25 million fundraising event hosted at one of Donald Trump’s golf courses, despite the President’s recent calls for the pharmaceutical company to lower its drug prices, according to sources.
Pfizer CEO Albert Bourla is expected to attend a fundraiser for President Trump’s super PAC, MAGA Inc., at his golf club in Bedminster, New Jersey. The event aims to raise $25 million. However, the meeting comes at an interesting time, as President Trump has been putting pressure on pharmaceutical companies, including Pfizer, to lower drug prices in the US. Just a day before the fundraiser, the President sent letters to 17 drug companies, including Pfizer, demanding that they lower prices to match those in other countries.
The letters asked the companies to commit to selling drugs at “most favored nation” rates, which would mean that the US would pay the same price as the country with the lowest price for a particular drug. The President has been pushing for this change, signing an executive order in May that told federal officials to draw up regulations to achieve this goal unless the pharmaceutical companies made progress on their own.
President Trump has been vocal about his efforts to lower drug prices, saying that he has “gone to war” with the pharmaceutical companies and other countries on the issue. He claims that he will be successful in bringing down prices by as much as 1,200 percent. The high cost of prescription drugs has been a long-standing issue in the US, with both parties proposing solutions over the years.
The pharmaceutical industry has pushed back against the idea of price caps, arguing that they could discourage innovation and make it harder to fund research and development for new drugs. However, the President is determined to make a change, and his meeting with Bourla and other pharmaceutical executives will likely be closely watched.
Bourla has a history of engaging with President Trump, having worked with him on the development of COVID-19 vaccines through the “Operation Warp Speed” program. He also met with the President at Mar-A-Lago two weeks before his second inauguration. The meeting between the two will be interesting, given the President’s recent demands for lower drug prices. CBS News has reached out to Pfizer and the White House for comment on the matter.